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 INTRODUCTION 
 Ovarian tumors accounts for 6% of all cancer in women
49
 .Ovarian 
tumors are the 5
th
 leading cause of cancer death in women in India
49
. Annual 
incidence rate in India is 9.0 per 100,000 population.Ovarian tumors accounts 
for 30%  among all  tumors of female genital tract 
58
. 
 Tumors of ovary generally are more prevalent in the upper socio-
economic groups due to their low fertility rate and there is aracial predisposition 
of ovarian cancers with increased risk of Caucasians and lower risk for black 
women 
70
.    
About two-thirds of ovarian tumors occurs in reproductiveage group. 
Many risk factors are associated with increasedprevalence of ovarian tumors 
most importantly ,age ,positive family history,genetic factors,hormonal and 
reproductive factors
42
. 
  Most cases are sporadic, only around 5-10% of ovariancancers are 
Hereditary. Women having  inherited mutations in BRCA-1 & BRCA2 tumor 
suppressor gene are at  increased risk for developing the tumor 
14,42
. 
Abdominal USG & Serum CA-125 measurement were usedas screening 
methods for diagnosis of early ovarian carcinoma. Fine needle aspiration 
cytology is used for primary diagnosis in a patient with advanced disease and 
also to monitor recurrences after treatment with an overall accuracy of 
differentiating benign from malignant ovarian tumor ranging from 90-95% 
51
. 
Preventive measures that could be recommended onpopulation wide basis 
are diet modifications, cessation of smokingand prophylactic oophorectomy 
isusually done in patients having higher risk .
14
. 
Despite the development of  new diagnostic andtherapeutic strategies to 
improve the 5- yr survival rate ,ovariancancer still remains the deadliest due to 
the fact that most of them are diagnosed only in advanced stages of disease 
where 5-yr survival rate falls less than 20% and partly it is due to paucity of 
knowledge about exact etiological factors
48
. 
Any persistent ovarian enlargement is an immediateindication for surgical 
assessment and actual diagnosis rests with the histopathological examination of 
specimen. WHO Histological Classification is used for the  diagnosis  of 
ovarian tumors. They are categorised into 3 major categories 1.Surface 
epithelial -stromal.2. Sex cord –stromal 3. Germ cell tumors 44,49. 
Histological subtyping of surface epithelial stromal tumorsinto Benign, 
Borderline & Malignant has therapeutic and prognostic significance. 
Histological grade is an important independentprognostic factor in patients with 
surface epithelial stromal tumor 
49
. 
Ovarian serous carcinoma is classified according to 2-tier grading system 
into low and high grade and it is based on the biological evidence that these 
tumors develop from different pathways of gene alterations
3
. p53 
immunohistochemical staining is done to provide an update on pathogenesis  of 
low & high grade serous carcinoma and also helps in understanding the 
pathogenesis of Type I & Type II ovarian carcinomas
3
.  
Ki-67 is a cell proliferation marker. MIB1 is a murinemonoclonal 
antibody against ki-67 antigen
8
. Ki-67 labelling index helps in the differential 
diagnosis of surface epithelial stromal tumors of ovary
34,35
. 
This study is undertaken in order to evaluate theincidence of ovarian 
neoplasms in our institution with refrerrence to age, clinicopathological 
features, histopathological and  immunohistochemical features along with 
immense review of journals and research publications. 
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AIM OF THE STUDY 
1. To study and compare the incidence of ovarian tumors in our institution 
along  with clinical correlation. 
 
2. To study and compare the incidence of malignant ovarian tumors in  our 
institution in relation to malignancies occurring in female genital  tract . 
 
3. To justify the use of Two-tier grading system in ovarian serous carcinomas 
in routine practice. 
 
4. To determine whether p53 mutations seperates Type I and Type II epithelial 
ovarian carcinomas and to provide support for new theory of ovarian 
carcinogenesis. 
 
5. To determine whether Ki-67 (LI) helps in differentiating borderline and 
malignant surface epithelial tumors. 
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 MATERIALS AND METHODS 
 A total of 150 cases of ovarian neoplasms referred from Raja Mirasudhar 
Govt.Hospital (RMH) , Thanjavur Medical college during 2010 to 2012 were 
included in this study. We received unilateral, bilateral salphingo-oophorectomy 
along with total abdominal hysterectomy and ovariotomy specimens. Specimens 
were fixed in toto in  10%  neutral buffered formalin and processed routinely. 
 In cystic ovarian neoplasms, 4-5 bits were taken from the wall alongwith 
papillary excrescencess if present. In solid tumors,3-4 bits were taken if the 
tumors were less than 5 cm. If more than 5 cm, one block per 1 cm of the tumor 
were taken across its greatest dimension, particularly if the appearance is 
variegated. 3-4 micrometre sections were cut and stained with haematoxylin and 
eosin (Appendix I) . 
 H&E stained sections were reviewed in all cases. The following 
clinicaland histological parametres were evaluated in particular patients age 
,tumorsize,stage of disease(FIGO staging),Histological Type & Subtypes were 
done according to WHO Classification criteria. For serous carcinomas 
,histological grade was done according to recent two-tier grading system. 
 The immunhistochemical detection of biomarkers in suface epithelial 
stromal tumors were conducted using monoclonal primary antibody (anti-ki67 
and anti-P53) against Ki-67 nuclear antigen and P53 gene respectively. 
{Appendix II} 
 
 
 
Ki-67  Immunostaining: 
 The conventional 3-4 micro metre sections were cut from paraffinblocks 
and the immunohistochemical staining procedure was performed using the heat 
induced antigen retrieval method with specific murine monoclonalantibody-
MIB1 and labelling index was done. Labelling index was measured as 
percentage of MIB-1 positive cells in a 1000 randomly selected tumor 
cells.Only nuclear staining was regarded as positive; weak nuclear or 
cytoplasmic staining was regarded as negative. 
 P53 Immunostaining: 
 3-4 micrometre tissue sections were deparaffinised and steamed incitrate 
buffer for 5 minutes to facilitate antigen retrieval. The slides were then 
incubated with monoclonal antibody that reacts with p53 protein. Results 
wereinterpreted as Positive when cells shows diffuse and intense nuclear 
staining,Weakly stained sections are considered as negative.                    
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 REVIEW OF LITERATURE 
GROSS ANATOMY 
 Ovaries are paired, almond shaped pelvic organs weighing 5-8 gms. Each 
ovary measures 3x2x1 cm in an adult, lies on either side of uterus close to the 
lateral pelvic wall.
37,74 
Each ovary is attached to posterior aspect of broad ligament by the 
mesoovarium and is attached at its medial pole to ipsilateral uterine cornu by 
ovarian ligament. The lateral pole of ovary attaches to pelvic wall by 
infundibulopelvic ligament which contains the principal vascular supply 
andlymphatic drainage  of the ovary
74
. 
 
 
 
 
 
 
 
FIGURE 1: Schematic diagram of Female genital tract. 
 
 
Cut surface 
Shows narrow white outer cortex and a greyish pink,medulla thatforms 
the bulk of the organ. In adults,ovary shows thin walled fluid filled cystic 
follicles and bright yellow corpora lutea is readily visible . 
 
 
  
 
 
 
 
EMBRYOLOGY:  
At approximately 5 weeks of gestation; thickenings of the lining of posterior 
embryonic body cavity forms the genital ridges continued into the underlying 
primitive connective tissue known as mesenchyme, leads to the formation of 
primordial indifferent gonads. At 2 months of gestation, primitive gonad is 
recognised as an ovary because of lack of development of welldefined testicular 
sex cords. Mesonephric cells and germ cells remain closely associated forming  
ill defined ovarian sex cords embedded inprimitivemesenchyme. The coelomic 
epithelium remains at the periphery, enwrapping the developing ovary(37). 
 
 
 
HISTOLOGY: 
 The ovary is covered by a single layer of cells originates from the 
coelomic epithelium. This is a highly specialised mesothelial layer called as 
surface epithelium becomes continues with the mesothelium of peritonealcavity. 
The cells can be flattened, cuboidal, columnar or focally pseudo-stratified.  
 Beneath the surface epithelium lies the cortex,which is roughly divisible 
into outer fibrous acellular collagenous zone termed as ‘Tunica albuginea’ and 
inner more cellular active cortex. Inner cellular cortex contains the primordial 
follicle, ripening follicle and mature follicles. The stroma.consists of uniformed 
spindle cells in bundles often with storiform pattern(75) 
The central portion of the ovary is the medulla and it also has 
activefollicles and cellular stroma. The blood vessels enter at the hilum 
areaccompanied by a small amount of connective tissue. 
The hilus cell nests are unencapsulated variably sized aggregates liesin 
the ovarian hilar region and adjacent mesoovarium. These hilus cells are round-
oval,contains abundant eosinophilic cytoplasm and vesicular nucleus & one or 
two nucleoli. Hilus cells contain specific crystals of Reinke, which are 
homogenous; eosinophilic, non refractile rod shaped structures. 
 
 
 
 
 
 
OVARIAN TUMORS:                    
 Tumors of the ovary represents about 30% of all cancers of femalegenital 
tract system. Age adjusted incidence rates are highest in economically advanced 
countries(5). 
 Environmental,genetic and life style factors all influence ovarian cancer 
risk.Genetic susceptibility is evident from numerous epidemiological 
investigations and there was increased susceptibility in patients with positive 
family history.  A number of specific genes most important of which is 
BRCA1and  BRCA 2 .  Ovarian cancer is a minor feature of the hereditary 
nonpolyposis colon cancer syndrome(53) 
 Parity, OCPs intake are associated with decreased risk for ovarian 
carcinomas(14). Higher risk is found to be associated with primary infertility, 
early menarche, late menopause ,obesity ,higher fat intake. Positive family 
history is strongly associated with development of ovarian cancer. 
Womenwhose first degree relatives have ovarian cancer have 3 times increased 
risk for developing the disease when compared to unaffected relatives(41). 
 
 
 
 
 
 
 
WHO HISTOLOGIC CLASSIFICATION OF TUMORS OF 
THE OVARY 
Surface epithelial – stromal  
Serous tumors 
 Malignant  
 Adenocarcinoma 
 Borderline tumor  
 Benign - Cystadenoma, adenofibroma, cystadenofibroma  
Mucinous  tumors 
 Malignant  
 Adenocarcinoma 
 Borderline tumor 
 Benign - Cystadenoma,adenofibroma,cystadenofibroma 
 Mucinous cystic tumor with pseudomyxoma peritonei 
Endometrioid tumors 
 Malignant  
 Adenocarcinoma 
 Malignant mixed mullerian tumor 
 Endometrial stromal sarcoma 
 Borderline tumor 
 Benign - Cystadenoma,adenofibroma,cystadenofibroma 
Clear cell tumors 
 Malignant  
 Adenocarcinoma 
 Borderline tumors 
 Benign -  Cystadenoma , adenofibroma, cystadenofibroma 
Transitional tumors 
 Malignant  
 Transitional cell carcinoma(non –Brenner type)   
 Malignant  Brenner tumor 
 Borderline 
 Benign - Brenner tumor 
Squamous cell carcinoma 
Mixed epithelial tumors 
 Malignant 
 Borderline 
 Benign 
Undifferentiated and unclassified tumors 
 Undifferentiated carcinoma 
 Adenocarcinoma, not otherwise specified 
 Sex cord – stromal tumors 
 Granulosa – stromal cell tumor 
 Granulosa cell tumor 
 Adult  granulosa cell tumor 
 Juvenile granulosa cell tumor 
 Thecoma-fibroma  group 
 Thecoma,not otherwise specified 
 Typical 
 Luteinized 
 Fibroma  
 Cellular fibroma 
 Fibrosarcoma 
 Stromal tumor with minor sex cord elements 
 Sclerosing stromal tumor 
 Signet ring –stromal tumor                   
Sertoli – stromal cell tumors 
Sertoli- Leydig cell tumor group 
 Well differentiated 
 Of intermediate differentiation 
  Variant with heterologous elements  
 Poorly differentiated 
  Variant with heterologous elements 
 Retiform 
  Variant with heterologous elements 
 Sertoli cell tumor 
 Stromal –Leydig cell tumor 
 Sex cord –stromal tumors  of mixed or unclassified cell type 
 Sex cord  tumor with annular tubules 
 Gynandroblastoma 
 Sex cord-stromal tumors,unclassified 
 Steroid  cell tumors 
 Stromal luteoma       
 Leydig cell tumor group 
  Hilus cell tumor 
  Leydig cell tumor .non hilar type 
  Leydig cell tumor, not otherwise specified 
 Steroid cell tumor, not otherwise specified 
  Well differentiated 
  Malignant 
Germ cell tumors 
 Primitive germ cell tumors 
 Dysgerminoma 
 Yolk sac tumor 
 Embryonal carcinoma 
 Polyembryoma 
 Non gestational chorio carcinoma 
 Mixed germ cell tumor 
 Biphasic or triphasic teratoma 
 Immature teratoma 
 Mature teratoma 
  -Solid 
  -Cystic 
  -Fetiform teratoma 
 Monodermal teratoma and somatic type tumors  
associated with dermoid Cyst 
 Thyroid tumor group  
   Struma ovarii  
 Benign 
 Malignant 
 Carcinoid tumor 
 Neuro ectodermal tumor group 
 Carcinoma group 
 Melanocytic group 
 Malignant melanoma 
 Melanocytic nevus 
 Sarcoma group 
 Sebaceous tumor group 
 Pituitary type tumor group 
 Retinal anlage tumor group 
Germ cell sex cord – stromal tumor 
 Gonadoblastoma - Variant with malignant germ cell tumor 
 Mixed germ cell – sex cord – stromal tumor - Variant with 
malignant germ cell tumor 
Tumors of the rete ovarii 
 Adenocarcinoma 
 Adenoma 
 Cystadenoma 
 Cystadeno fibroma 
Miscellaneous tumors 
 Small cell carcinoma, hypercalcemic type 
 Small cell carcinoma, pulmonary type 
 Large cell neuro endocrine carcinoma 
 Hepatoid carcinoma 
 Primary ovarian mesothelioma 
 Wilm’s tumor 
 Gestational choriocarcinoma 
 Hydatidiform mole 
 Adenoid cystic carcinoma 
 Basal cell tumor 
 Ovarian wolffian tumor 
 Paraganglioma 
 Myxoma 
 Soft tissue tumors not specific to the ovary 
Tumor-like conditions 
 Luteoma of pregnancy 
 Stromal hyperthecosis 
 Stromal hyperplasia 
 Fibromatosis 
 Massive ovarian edema 
Lymphoid and haematopeitic tumors 
Secondary tumors 
 
 
SURFACE EPITHELIAL STROMAL TUMOR: 
 Each of the tumor type is subdivided into Benign, Borderline, Malignant   
category.  Benign tumors of serous, mucinous, endometroid, clear cell are 
further subtyped into cystadenoma, cystadenofibroma, adenofibromas(94). 
SEROUS TUMORS: 
 The most common type of surface epithelial neoplasms areserous tumors 
. Approximately 60% Benign, 10% Borderline, 30% malignant(43). 
BENIGN SEROUS TUMORS: 
 Occurs most commonly in 5
th
 decade. 
GROSS: 
They are bilateral in 10-20% cases.They are usually unilocular , entirely 
cystic or can be partly cystic. Cysts filled with watery thin serous fluid 
,innersurface of the cyst wall can be smooth or papillary excrescences can 
beseen(43). 
HISTOLOGY:  
Cysts and polypoid excrescencess has single layer of ciliatedepithelium 
similar to that of fallopian tube. Nuclear atypia is seen. Psammoma bodies are 
infrequent with rare mitotic figures. Papillae when found are almost entirely 
made up of fibrous stroma(44). 
SEROUS BORDERLINE TUMOR: 
 They are common in 4
th
& 5
th
 decade. 
GROSS 
 They are bilateral in 25% of cases. They are usually cystic, containing 
watery or thick mucinous fluid and have surface or intracystic numerous 
papillary projections(28). 
HISTOLOGY: 
 Three most important diagnostic features (29)are: 
1.  Arborising  papillae (hierarchial branching) form  
increasingly smallerbranches ending in clusters of  
epithelial cells, detached from stroma . 
2. Varying degree of mild –moderate nuclear atypia. 
3. Absence of frank stromal invasion/solid sheets of tumor  
with cribriform pattern (43).  
Serous borderline tumors are  classified into:  
1. Typical(90%) 
2. Micropapillary(10%) . 
 Typical serous borderline tumorsmakes up the majority and has aclassic 
branching papillary architecture and epithelilal tufts overlying the papillae. 
Micropapillary pattern shows focal or diffuse proliferation of tumor cells 
in elongated,thin micropapillae with little or no stromal support 
emergingdirectly from the cyst lining. The micropapillae are atleast five times 
as long asthey are wide,arising directly from the papillae with thick fibrous 
stalk. 
Having diagnosed a serous borderline tumor following features(81)  
should be  examined for: 
1. Surface involvement:  
Cross examination of ovarian surface is done carefully and it is oriented 
such that surface is evident on slide. The presence of surface involvement 
are associated with increased frequency of high stage tumor. Surface 
involvement enables peritoneal spread. 
2.  Stromal microinvasion: 
 Generous and judicious sampling is required to exclude microinvasion. 
Atleast one section per centimetre of tumor diameteris required. Invasive foci 
measuring less than 10mm2 and less than 3mm2 in greatest dimension is called 
as microinvasion.  
Microinvasive areas consist of either dyscohesive eosinophilic cells in 
cores of papillae. Individual cells have abundant eosinophilic cytoplasm and 
vesicular nuclei. Microinvasion by itself does not alter the overall behaviour of 
borderline ovarian tumors,but will co-seggregate with more aggressive tumors; 
in which case  micropapillary pattern is more ominous. 
3. Lymph node metastases: 
 Pelvic and paraaortic lymphnode metastases are found in as many as 27% 
of cases .These metastases are present in sinusoidal spaces rather than substance 
of node. Its presence does not alter the prognosis of serous borderline tumors, 
however they have lower disease free survival. 
 
4.  Implants on peritoneal surface: 
Implants can be invasive and non invasive. Presence of peritoneal 
implants and whether or not they are invasive are the most important indicators 
of outcome in serous borderline tumors. on invasive implants are of 2 types. 
Epithelial & Desmoplastic (12) . 
Epithelial implants: implants composed of papillae resembling those within 
ovarian serous borderline tumor. they are found either in mesothelial lined 
invaginations of peritoneal surface or between the lobules of fat. 
Desmoplastic implants : Papillae, glands, cell cluster or single cell within 
inflamed ;dense fibroblastic or granulation tissue that appearsto be plastered 
onto serosal surface. 
Invasive implant: 
1. Implants with haphazardly arranged glands involving the normal 
tissues such as omentum. 
2. Loose or dense fibrous reaction without significant inflammation  
3. Dominant epithelial proliferation 
4. Nuclear features resembling low grade serous carcinoma     
5. Irregular borders  and 
6.  Aneuploidy 
SEROUS BORDERLINE ADENOFIBROMA AND 
CYSTADENOFIBROMA: 
 In this variant epithelial lining of glands and or cysts of the adenofibroma 
or cystadenofibroma has the features of serous borderlinetumor instead of 
benign epithelium.(81) 
MALIGNANT SEROUS CYSTADENOCARCINOMA: 
GROSS:  
 They are bilateral in approximately 70% of cases. They range from 
microscopic size to more than 20cm dm. Mostly they are cystic and solid with 
papillae within cysts or on surface. Poorly differentiatedtumors are 
predominantly solid, multinodular masses with necrosis and haemorrhage(43)          
MICROSCOPY: 
 Most serous carcinomas are high grade tumors and frequently shows 
obvious stromal invasion. Architecturally, tumor varies from glandular,papillary 
to solid pattern.glands are typically slit-like. Papillae shows irregular branching 
and highly cellular.poorly differentiated tumors showspredominantly solid 
areas. Psammoma bodies  varies in number.stroma may be scanty or 
desmoplastic(92,103). 
 
 
 
 
  
GRADING:Various grading systems are in use .The most commonly used 
grading system was Silverbergs  grading system which is as follows (94) 
TABLE 1: Silverberg grading system: 
Score Architecture Cytologic atypia Mitotic figures/10hpf 
1 Glandular Mild 0-9 
2 Papillary Moderate 10-24 
3 Solid Severe >25 
Score 3-5: Grade 1 
Score 6-7: Grade 2  
Score 8-9: Grade 3 
2 –TIER GRADING SYSTEM FOR SEROUS CARCINOMA3:  
 According to Anais Malpaica et al ,Serous carcinoma is graded according 
to degree of nuclear atypia and  mitotic rate is used as secondary feature. 
Low grade:  
     1.  Mild to moderate  nuclear atypia and as secondary feature 
2.< 12 mitoses/10hpf. 
High grade 
    1.  Marked nuclear atypia and as secondary feature  
   2.  > 12 mitoses/10 hpf  and  multinucleated cells. 
 
Significance of 2 tier grading system: 
 Serous carcinomas are graded into low and high grade which reflect a 
difference in the pathogenesis of these tumors(3). Since the system is based on 
defined criteria that are easy to follow and because it involves only two 
diagnostic categories ,it provides better reproducibility in the grading  of serous 
carcinoma(80). 
Accordingly low grade serous carcinomas will not show  p53expression 
as these tumors have intact  p53 gene 
80
.In contrast more than 95%of high grade 
serous carcinomas shows strong positivity with p53 immunostaining indicating 
that this gene is involved in their tumorigenesis. 
 MUCINOUS TUMORS OF OVARY 
 The second most common type are mucinous tumors .About 80% 
ofmucinous tumors are benign,10% are borderline,10% malignant(6). 
BENIGN MUCINOUS TUMORS: 
GROSS: 
 They are large,unilateral,multilocular cystic masses containing viscous 
mucoid material. Cystadenofibromas are partially to almost completely solid. 
MICROSCOPY:  
 Mucinous columnar epitheliumcontaining intracytoplasmic mucin lines 
the glands and cysts, which resembles endocervical or gastrointestinal type 
epithelium.Cystadenofibromas shows mucinous glands and cysts uniformly 
distributed in a fibromatous stroma(93). 
BORDERLINE MUCINOUS TUMORS: 
 
INTESTINAL TYPE: 
GROSS:  
 About 85% of mucinous borderline ovarian tumors are of intestinal type. 
Bilateral in only 5% cases. They are large,cystic,multi/unilocular with viscous 
fluid. Borderline foci can be solid but typically reside within fleshy polypoid 
areas in cyst wall.(6,21) 
MICROSCOPY: 
 In addition to conventional benign mucinous 
cystadenoma,borderlineareas shows stratification ,no more than 3 layers and 
may form filliformintracystic papillae with minimal support. Nuclei are 
enlarged hyperchromaticand have increased mitotic activity. Goblet cells are 
seen distributed haphazardly. Glands and cysts lumen contain mucin(6). 
ENDOCERVICAL TYPE: 
GROSS: 
 About 10-15% of borderline tumors are endocervical type. They 
arebilateral in 40% cases and sometimes arise within endometriotic cysts(94). 
MICROSCOPY: 
 Broad bulbous papillae associated with cell stratification andepithelial 
tufting. The papillae are lined by both mucinous columnar cellsresembling  
endocervix and stratified polygonal eosinophilic cells characteristically many 
acute inflammatory cells are seen within thepapillae/free floating in the 
extracellular spaces(42).Both intestinal and endocervical type can be associated 
with noninvasive and invasive type implants in the peritoneum(53). 
 
MUCINOUS CYSTADENOCARCINOMAS 
GROSS: 
 Only about 5 % of these tumors are bilateral. They are large,unilateral, 
smooth surfaced; multilocular cystic masses containing viscous fluid. 
Haemorrhagic, necrotic, solid, papillary areas are relatively frequent. For all 
grossly suspicious areas, one histological section per 1-2 cm of tumor diameter 
is recommended. 
MICROSCOPY: 
 There are 2 forms of stromal invasion. Expansile and  infiltrative. 
Inexpansile invasion, glands and cysts are lined by malignant cells forms 
complexpapillary areas or back- back arrangement of glands with little/no 
discernableintervening stroma. To qualify as frankly invasive, such areas should 
be atleast10mm2.(77) 
In infiltrative type of invasion; glands, tubules, cords, cell 
nestshaphazardly infiltrate the stroma.The invasive cells has nondescript 
eosinophilic cytoplasm(77). 
MUCINOUS CYSTIC TUMOR WITH PSEUDOMYXOMA PERITONEI: 
 Pseudomyxoma peritonei is a clinical terminology that describe the 
presence of abundant  gelatinous material within pelvis and abdominal cavity 
surrounded by fibrous tissue. First step is to exclude the presence of appendiceal 
neoplasm or other gastrointestinal primary mucinous tumor metastasis to 
peritoneum. 
ENDOMETROID TUMORS: 
BENIGN ENDOMETROID TUMORS: 
 
GROSS: 
 These tumors average 8-10cm in dm. They are solid, firm,tan tumors with 
cysts of varying sizes(84). 
MICROSCOPY: 
 They are well differentiated,benign appearing glands or cysts lined 
byendometrial type cells with or without squamous differentiation(84). 
BORDERLINE ENDOMETROID TUMORS: 
GROSS: 
 These tumors are predominantly unilateral ,ranging in size from 2-40cm; 
cut surface gry-white to tan,can be solid and cystic or predominantly solid. 
Larger tumors shows haemorrhage and necrosis(92) 
MICROSCOPY: 
 Islands of crowded endometroid glands or cysts lined by cellsdisplaying 
grade 1 to grade 3 cytologic atypia proliferate in an  adenofibromatous stroma. 
Absence of stromal invasion and low mitotic activity is seen. About 15-50 % of 
patients have endometriosis in same ovary as well as at extraovarian sites(92). 
 
ENDOMETROID ADENOCARCINOMAS: 
GROSS: 
 These tumors measures on an average 10-20 cm in dm, solid, friable 
orCysts with mass protruding into lumen. They are bilateral in about 28% 
cases(74) 
 
MICROSCOPY: 
 Well differentiated tumors shows round,oval or tubular glands lined 
bystratified nonmucin containing epithelium. Squamous differentiation occurs 
in30-50% cases often in the form of morules(74). 
 
Table2:FIGOGrading scheme for Endometrioid adenocarcinoma: 
 
 
 
 
 
 
 
 
 
 
MALIGNANT MIXED MULLERIAN TUMOR: 
GROSS: 
 They are bilateral in 90% cases. They are large tumors partly solid 
andpartly cystic, bosselated  masses with  hemorrhage and necrosis(44). 
 
 
Grading Histological feature 
Grade 1 or well differentiated Well formed glands resembling 
villoglandular carcinoma of uterine 
corpus, < 5%  solid tumor growth. 
Grade 2 or moderately 
differentiated 
More complex glandular 
architecture,increased nuclear 
stratification,6-50% solid tumor 
growth. 
Grade 3 or poorly differentiated Poorly formed glands,large sheets of 
cells ,> 50% solid tumor growth. 
MICROSCOPY: 
 Biphasic neoplasm that has malignant epithelial and mesenchymal 
component. Epithelial component can be any type of surface epithelial 
carcinoma.mesenchymal component most commonly seen are fibrosarcomaor 
endometroid  stromal  sarcoma  or  leiomyosarcoma(44). 
 
ADENOSARCOMA: 
GROSS:  
Almost always unilateral and is predominantly solid with small cysts. 
MICROSCOPY: 
 Biphasic tumor in which mesenchymal component is sarcomatous 
butepithelium is benign. Cellular stroma forms periglandular cuffing. 
Adenosarcoma of ovary has worse prognosis when compared to its 
uterinecounterpart.(44) 
ENDOMETRIAL STROMAL SARCOMA: 
GROSS:More than 70% tumors are unilateral. most of them are solid and firm 
but some have cysts filled with mucoid or haemorrhagic fluid. 
 
MICROSCOPY: 
More than 50% cases are associated with endometriosis. Neoplastic cells 
are round to oval with round nuclei and scanty cytoplasm,arrangedhaphazardly 
in diffuse pattern. Hallmark is the presence of abundant small thick walled 
vessels. These vessels are surrounded by whorls of neoplastic cells(44). 
CLEAR CELL TUMORS: 
BENIGN TUMORS:    
GROSS: 
 External surface is smooth lobulated . Cut surfaceshows honey- combing  
appearance with tiny cysts embedded in rubbery stroma.(45) 
MICROSCOPY: 
 Tubular glands lined by 1 or 2 layers of epithelium that 
containsPolygonal cells whose cytoplasm is clear with minimalnuclear 
atypia.(45) 
BORDERLINE CLEAR CELL TUMORS: 
 GROSS:Smooth lobulated external surface with cut section appearing 
moresoftier and fleshier. 
MICROSCOPY:Tumor composed of tubules and small cysts lined by 
one or several layers of cuboidal epithelial cells with clear cytoplasm or hobnail 
nuclei. Epithelial cells shows mild to moderate nuclear atypia and occasional 
mitotis(44) 
 
CLEAR CELL ADENOCARCINOMA: 
GROSS: 
 These tumors have an average size of about 15cm. Cut section shows  
unilocular cyst with yellow nodules with some cysts containing 
watery/mucinous fluid. They are seen associated withendometriosis ovary(44).  
MICROSCOPY: 
 These tumors shows tubulocystic, papillary and solid patterns.Individual 
cells are polyhedral cells with abundant clear cytoplasm separated by delicate 
fibrovascular stroma in solid pattern(44).           
TRANSITIONAL TUMORS: 
BENIGN BRENNER TUMOR:        
GROSS: 
 More than 50% tumors are less than 2 cm dm. They are well 
circumscribed firm,white gritty on sectioning with focal areas of calcification. 
Brenner tumors are associated with mucinous cystadenoma in about 25% 
Cases(76) 
MICROSCOPY: 
 Nests of  transitional type of  epithelial cells withcentrally grooved coffee 
bean nuclei with abundant eosinophilic cytoplasm and distinct cell membranes. 
These nests lie in a predominantly fibromatous stroma.(76) 
 
BOREDRLINE BRENNER TUMOR: 
GROSS: 
 They are typically large with mean diameter of 16-20cm, usually has 
solid and cystic component. 
MICROSCOPY:  
 These tumors shows branching papillae lined by transitional epithelium 
which  protrudes into cystic spaces. There is absence ofstromal invasion. A 
benign Brenner component is typically present.(76) 
MALIGNANT BRENNER TUMOR: 
GROSS: 
They are large tumors, has solid component as well as cystscontaining 
papillary or polypoid masses. 
MICROSCOPY: 
These tumors exhibits stromal invasion associated with a benignor 
borderline Brenner component. Invasive element is usually high 
gradetransitional cell carcinoma(93). 
TRANSITIONAL CELL CARCINOMA: 
GROSS: 
 They are bilateral in about 15% cases , often partly solid & cystic. 
 
 
MICROSCOPY: 
 They have papillary architecture lined by multilayered transitional 
epithelium, cells shows features of malignancy and these tumorsshould not have 
a benign or borderline Brenner component.(93) 
MIXED EPITHELIAL TUMOR: 
MICROSCOPY: 
 These tumors consists of admixture of 2 or more of 5major cell types: 
serous, endometroid, clear cell, Mucinous and transitional.(76) 
UNDIFFERENTIATED CARCINOMA: 
MICROSCOPY: 
It is a primary ovarian tumor with no differentiation and marked 
cytological atypia.(76) 
B. SEX CORD – STROMAL TUMOR : 
GRANULOSA CELL TUMOR: 
These tumors constitute for about 1.5% of all  tumors of ovary(76). 
ADULT TYPE: 
GROSS: 
 They are unilateral in 95% of cases. On an average size of 12 cm and 
encapsulated. Cut section shows solid and cystic,areas of necrosis and 
haemorrhage  giving a variegated appearance.(1) 
 
MICROSCOPY: 
There is proliferation of granulosa cells often with a stromal component 
of fibroblasts, theca or lutenised cells. Individual cells have scanty cytoplasm 
with longitudinal nuclear grooves. There is minimal to no cytological atypia and 
a low mitotic activity (1,76).  
These tumors shows different histological patterns including 
microfollicular, macrofollicular, watered silk, gyriform and diffuse. 
(1,76).Mostcommon pattern is  microfollicular characterised by the presence of 
call-exnerbodies. Fibrothecomatous  stroma  often surrounds granulosa cells. 
 
 
JUVENILE TYPE: 
Occurs predominantly before 30 yrs age group . In prepubertalgirls 90% 
are associated with isosexual pseudo precocity.(76) 
GROSS: 
These tumors are indistinguishable from adult type granulosa cell  tumor . 
MICROSCOPY: 
These tumors shows nodular or diffuse cellular growth punctuatedby 
macrofollicles of varying sizes and shapes. Their lumen contain eosinophilic or 
basophilic fluid.  Typically rounded neoplastic granulosa cells has abundant 
eosinophilic and or vacuolated cytoplasm and almost all nuclei lack grooves. 
Abundant mitotic figures seen.(1,76) 
 
 
THECOMA –FIBROMA: 
THECOMA 
GROSS: 
 These tumors occur in postmenopausal women .They have anaverage size 
of about 5-10 cm. Cut section shows solid and yellow and almost always 
unilateral.(93)      
MICROSCOPY: 
Tumor cells are uniform ,bland oval to spindle shaped nuclei with 
abundant pale vacuolated lipid rich cytoplasm. Individual cells are invested by 
reticulin. Mitoses are absent. Calcifications are commonly seen .Luteinised 
thecomas  contain  lutein cells ,individually or in nests, in a background more 
often fibromatous than thecomatous. Oedema and microcyst formation is 
striking(93). 
FIBROMA:GROSS: 
 They account for 4% of all ovarian tumors.they are hard whitetumors. 
Majority of them are unilateral.(40). About 10-15% of tumors are large and 
often associated with ascites and  Meigs syndrome(4). 
MICROSCOPIC: 
These tumors composed of spindle shaped cells with uniform bland 
nuclei and scant cytoplasm, arranged in fascicles or in a storiform pattern. 
Mitoses are absent. About 10% are  uniformly and densely cellular and are 
referred as cellular fibromas.(4,40) 
 
FIBROSARCOMA: 
GROSS: 
 Large, solid tumors, haemorrhagic and necrotic  and usually unilateral. 
MICROSCOPIC: 
 These tumors are densely cellular with moderate to severecytological 
atypia, high mitotic rate and atypical mitotic figures with haemorrhage and 
necrosis.(94) 
SCLEROSING STROMAL TUMOR: 
GROSS:They are typically unilateral and well circumscribed averaging 15cm 
in dm. Cut section shows solid,grey white with occasional yellow foci(94). 
MICROSCOPY: 
 These tumors shows pseudolobulation of cellular areasseparated by 
hypocellular areas of densely collagenous stroma. Cellular areas shows 
prominent thin walled vessels, some of them having HPC-like pattern. 
SIGNET-RING  STROMAL  TUMOR : 
GROSS:   
 These tumors may be  both solid and cystic or uniformly solid. 
 
 
MICROSCOPY: 
 H& E section shows a diffuse proliferation of spindle and round cells, 
latter shows eccentric nuclei with a single large intracytoplasmic vacuole and 
resemble signet ring cells(93). 
SERTOLI-STROMAL CELL TUMOR: 
SERTOLI-LEYDIG CELL TUMOR GROUP: 
They are rare and comprises of  less than 0.5% of all ovarian tumors. 
GROSS:Majority of them are unilateral.they are solid or solid and cystic.Solid 
areas are fleshy,pale yellow with areas of haemorrhage and necrosis.(94) 
MICROSCOPY: 
1. Well differentiated(Meyer’s type I)  tumors, sertoli cells are 
present in open or closed tubules and lack significant nuclear 
atypia or mitotic activity. 
2. Intermediate,( Meyer’s type II)- Composed of cords, sheets and 
nests of sertoli like cells separated by spindle stromal cells 
3. Poorly differentiated( sarcomatoid ,Meyers type III)-they are 
arranged in sarcomatoid pattern with  masses of spindle 
shapedcells.(94) 
SERTOLI CELL TUMOR: 
 They are commonly seen in women of reproductive age group. 
GROSS: 
 Pure  forms of sertoli cell tumors are rare. They are mostly unilateraland  
average size of  5-7 cm diametre in size.(76) 
MICROSCOPY: 
 These tumors composed of sertoli cells that line tubules or trabeculaeor 
grow in nests or solid sheets. Cells are columnar or polygonal and have small 
round to oval nuclei and granular or eosinophilic cytoplasm, with minimal 
nuclear atypia. (76).              
GYNANDROBLASTOMA: 
 Gynandroblastoma is a rare tumor ,containing both sertoli cells orsertoli-
leydig cell and granulosa cell differentiation. They are usually unilateral with 
size ranging from 1-18cm. Microscopically tubules and trabeculae similarto 
those in well differentiated sertoli or sertoli-leydig cell tumors mixed with nests 
and sheets of granulosa cells.(76)        
STEROID CELL TUMOR: 
 
 
GROSS: 
 They are large and usually well circumscribed often lobulated 
appearance. Sectioned surface ranges from yellow to brown or black. 
MICROSCOPY:  
 These tumors shows solid aggregates of cells withoccasional nests or 
trabeculae. Tumor cells are polygonal with granular and eosinophilic 
cytoplasm,nuclei are usually bland. Areasof haemorrhage and necrosis can be 
seen(94).                                                                                  
C. GERM CELL TUMORS: 
INTRODUCTION :  
These tumors account for 30% of primary neoplasms of ovary, 95% of  
which are dermoid cysts(mature cystic teratomas). Median age at presentation 
is 18 years. Malignant GCT are common cancers among children and 
adolescent females. (94) 
DYSGERMINOMAS: 
GROSS: 
Well encapsulated tumor ,unilateral in 90% of cases. Average tumor size 
is 15cm dm. Section shows solid,uniform or lobular and creamy white. Foci of 
coagulative necrosis and cystic change or macroscopic calcification can be 
seen.(15) 
MICROSCOPY: 
 Tumor shows sheets of monotonous appearing polygonal cells with 
abundant pale cytoplasm and fairly uniform vesicular nuclei with prominent 
nucleoli. Tumor cells found in lobules separated by thin fibrous septainfiltrated 
with lymphocytes. syncytiotrophoblastic cells are found in around 5% of 
cases.(15) 
YOLK SAC TUMOR: 
GROSS: 
They are well encapsulated tumor with an average size of 15cm dm.Cut 
section shows grey yellow areas with frequent areas of necrosis, haemorrhage 
and liquefaction. Cysts are also seen.(39) 
 
MICROSCOPY: 
 Tumor shows the characteristic reticular pattern formed by aloose, 
myxoid stroma harbouring a network of microcysts. These cysts are lined by 
clear or flattened epithelial cells. PAS +ve  hyaline globules are seen tumor. 
Only around 10-20% of tumors shows schiller-duval bodies.(39) 
EMBRYONAL CARCINOMA AND POLYEMBRYOMA: 
 They are rare tumors mostly reported as a component of mixedgerm cell 
tumors.(46) 
MICROSCOPY: 
Tumor shows dysorganised sheets of large primitive appearing cells 
forming papillae or crevices coexist with syncytiotrophoblastic cells as well as 
early teratoid differentiation.When abundant embryoid bodies are seenthis 
tumor is called as Polyembryoma .(46) 
MIXED GERM CELL TUMOR:  
These tumors are composed of atleast 2 different germ cellcomponents of 
which atleast one is primitive.(46) 
MICROSCOPY: 
 Most common combination found is yolk sac tumor anddysgerminoma. 
Some of the additional elements are immature/mature teratoma, polyembryoma, 
embryonal carcinoma, may be present.(46) 
BIPHASIC TERATOMA: 
These are tumors composed of derivatives of 2 or 3 germ layers. 
IMMATURE TERATOMA: 
GROSS: 
 Typically unilateral ,large,variegated predominantly solid. 
MICROSCOPY: 
 Tumor shows immature embryonal type tissues, in the form of 
neuroepithelial rosettes and tubules admixed with mature tissue. 
MATURE TERATOMA: 
 Most mature cystic teratomas occur in the reproductive agegroup. Mature 
solid  teratomas occur mainly in first two decades of life.(76) 
GROSS: 
 Dermoid cysts presents as cystic mass with an average size of 15cm dm, 
they are bilateral in 8-15% of cases. Cysts are often filled with hair and 
sebaceous material. Rokitansky protruberance is seen protruding into the 
cyst(76). 
MICROSCOPY: 
Tumor shows mature tissue from all three germ layers. most commonly 
squamous epithelium,sweat glands ,sebaceous glands. Mesodermalelements like 
smooth muscle, teeth, bone, respiratory epithelium, gastrointestinal epithelium 
are also seen.(76) 
 
 
 
MONODERMAL TERATOMAS: 
STRUMA OVARII: 
 Most common type of monodermal teratoma.  Accounts for 2-7% of all 
ovarian teratomas.(92) 
GROSS: 
 They are unilateral and size varies from 0.5-10 cm dm. Cut section brown 
solid and gelatinous nodules within a dermoid cyst(92). 
MICROSCOPY: 
Tumor is composed of normal or hyperplastic thyroid tissue withmicro or 
macrofollicular pattern trabecular and solid pattern. Most common malignancy 
in struma ovarii is papillary carcinoma with similar characteristichistological 
features as in tumors arising from thyroid gland.(92)  
CARCINOID TUMOR: 
Ovarain carcinoids account for 0.5-1.7% of all carcinoids(63). 
GROSS:Primary ovarian carcinoids are unilateral and present as firm,tannodule 
protruding into dermoid cysts. Cut section shows firm homogenous and tan to 
yellow(63). 
MICROSCOPY: Insular carcinoid consists of islands and nests of round cells 
withabundant eosinophilic cytoplasm and round uniform nuclei. 
Trabecularcarcinoids exhibits wavy and anastomosing ribbons composed of 
columnarcells with long axes ofcell parallel to one another(63). 
 
NEUROECTODERMAL TUMOR: 
GROSS:They are unilateral and an average size of 14 cm dm. Sectioned 
surfaceis solid with friable, gray pink ,tissue and cysts with papillary 
excrescencess. (85) 
MICROSCOPY: Well differentiated tumors forms like ependymomas and 
poorlydifferentiated tumors like medulloepithelioma and primitive neuro 
ectodermaltumor are seen. Anaplastic forms such as glioblastoma multiforme is 
alsoseen(85). 
CARCINOMA: Carcinoma secondarily develops from dermoid cysts. They 
usually occur in postmenopausal women(46). 
GROSS:Cauliflower like exophytic growth or infiltrative grey white 
plaqueswith necrosis and haemorrhage may be seen. 
MICROSCOPY:Most common type of carcinoma arises is squamous cell 
carcinoma accounting for 80% of cases. Second most common malignancy 
isadenocarcinoma.(46) 
SARCOMAS: 
MICROSCOPY:Accounts for 8% of cases of malignancy in dermoid cyst. 
Most cases are leiomyosarcoma, angiosarcoma, osteosarcoma, chondrosarcoma, 
fibrosarcoma. 
MELANOCYTIC TUMORS:They are rare tumors , dermoid cyst with 
melanoma in stage I  are alive  even after 2 yrs of diagnosis .(92). 
 
 
SEBACEOUS TUMORS: 
MICROSCOPY:Tumors like basal cell carcinoma with sebaceous 
differentiation, sebaceous carcinoma and sebaceous adenoma are common. 
Hallmark ofthese lesions is presence of large number of mature sebaceous cells 
with oil red O positive staining.(76)  
PITUITARY TYPE TUMORS:Corticotroph cell adenoma and prolactinomas 
are common(76). 
RETINAL ANLAGE TUMOR: Pigmented progonoma and malignant tumors 
derivedfrom the retinal anlage are seen.(95)       
GERM CELL-SEX CORD STROMAL TUMOR(93): 
GONADOBLASTOMA: 
 Most of these patients have gonadal dysgenesis and more than 90% cases  
have a Y chromosome.Typically seen in children or young 
adults.gonadoblastoma is a benign tumor unless a malignant germ cell 
component is seen.(93) 
GROSS:They are small with a yellow to tan grey cut surface and areas 
ofcalcification.(93) 
MICROSCOPY:Tumor is composed of 2 main cell types; germ cell similar to 
that ofdysgerminoma or seminoma and sexcord derivatives resembling 
immature sertoli cells. The stroma contains a lutenised orleydig –like cells 
devoid of reinke crystal. (93) 
MIXED GERM CELL-SEX CORD-STROMAL TUMOR: 
 Occurs in infants or children under the age of 10. One fourth of cases 
have isosexual pseudoprecocity.(94) 
GROSS:They are large tumors predominantly solid or partly solid &cystic. 
MICROSCOPY:Tumor is composed of germ cells and sexcord derivatives 
similar in apperaence to  immature sertoli/ granulosa cells intimately admixed 
with each other.(94) 
D: TUMORS OF RETE OVARII:Most of these lesions are incidental finding 
in a postmenopausal women.To diagnose, these lesions tumor must be located 
in ovarian hilus.(16)  
MICROSCOPY:Tumor is composed of cuboidal cells or columnar nonciliated 
cells arranged in retiform spaces.dilated areas and cyst are most frequently 
seen.(16) 
METASTATIC TUMORS:These tumors comprise about 5-10% of all 
ovariantumors. Primary tumors from gastrointestinaltract (especially large 
intestine, stomach, appendix), are most common followed by Breast, Uterine 
corpus and uterine cervix. In young girls ovarian metastases are common with 
neuroblastoma, rhabdomyosarcoma, Ewing sarcoma. (82,98). 
GENERAL FEATURES OF OVARIAN METASTASES: 
1. Bilaterality. 
2. Small superficial; Multinodular tumor 
3. Vascular invasion 
4. Desmoplastic reaction  
5. Extensive unusal extraovarian spread 
6. Unusual clinical history. 
GROSS:Ovarian metastases are bilateral in 70% of cases. Size of ovarian 
metastase varies from microscopic size to more than 10cm(16). 
MICROSCOPY:Metastatic tumors grow as superficial or parenchymatous 
solid nodules. Histologic nature depends on the primary tumor(16). 
KRUKENBERG TUMOR:They are defined characterised by thepresence of 
mucin –filled,signet ring tumor cells within cellular stroma of the ovary. Most 
krukenberg tumors  represent ovarian metastases from the gastrointestinal tract, 
especially stomach(59). 
p53: 
 p53 is a tumor suppressor gene situated on chromosome 17
45
P53 gene  
mutation results in uncontrolled cell proliferation. Approximately 50% of 
malignant tumors in humans have mutations in p53 gene and it is the Most 
common tumor suppressor gene involved with human malignancies.(66) 
Studies have shown that p53 gene is mutated in about 50 - 80% ofovarian 
carcinomas
31
. It has been identified that immunohistochemical detection of  p53 
protein overexpression, is an adverse prognostic factor for survival in human 
ovarian cancer
67
.   
The number of cases with mutant Tp53 among ovarian serous and 
endometroid carcinomas is 57% and 25% respectively with maximum value in 
the poorly differentiated tumors in patients with stage III or stage IV 
disease.One of the reasons for deranged p53 gene functions can be related to 
BRCA1 & BRCA2 mutations which are frequent event in hereditary ovarian 
Carcinoma
66
. 
Ovarian low grade serous carcinomas evolve from borderlinetumors and 
they lack p53 mutations but they often have mutations of KRAS & BRAF gene 
mutations(Type I pathway).In contrast ovarian high grade serous carcinomas 
arise as denovo and majority of them has p53 mutations and lack KRAS, BRAF 
gene   mutations(Type II pathway)
17
.Epithelial ovarian malignancies showing 
p53 aberrations aresignificantly less sensitive to chemotheraphy and more 
aggressive than those with functional p53 gene.
7
 
Ki-67:
 
 
Ki-67 is a cell proliferation marker. Ki-67 antigen immunostaining isused 
to estimate the proliferation index of a tumor
34
. This antigen ispreferentially 
expressed in late G1,S,G2& M phase except in G0 phase
8       
Determining the proliferative activity of ovarian tumors has reportedto be 
of diagnostic and prognostic value
22,34
. In paraffin section, MIB1 antibody is 
equivalent to ki-67. MIB1 is a murine monoclonal antibody reacts withthe Ki-
67 protein expressed by the proliferating tumor cells
23
.
 
MIB1 antibody staining provide a reliable means of 
identifyingproliferating normal and neoplastic human cells in histological 
sections
89,99
.
 
 Ki-67 immunostaining in ovarian malignancies is helpful in 
differentiatingborderline and malignant surface epithelial tumors of 
ovary.(22,27)          
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18. 1096/10 45 MASS ABDOMEN R-CYSTIC,L-CYST 
WITH 
PAPILLARY 
EXCRESENCES 
R-BORDERLINE 
MUCINOUS 
CYSTADENOMA  
L-SEROUS 
PAPILLARY 
CYSTADENOMA 
I 
19. 1107/10 40 PAIN ABDOMEN UNILATERAL- CONGESTED I 
Sl.No HPE.No AGE-YRs CLINICAL 
PRESENTATION 
GROSS FEATURE HPE DIAGNOSIS FIGOSTAG
ING 
1. 1/10 47 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN serous 
CYSTADENOMA 
I 
2. 66/10 45 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
3. 96/10 25 PREGNANCY 
ASSOCIATED 
UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
4. 232/10 24 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
5. 258/10 28 MASS ABDOMEN UNILATERAL –
CYSTIC 
MATURE CYSTIC  
TERATOMA 
I 
6. 314/10 50 ASYMPTOMATIC UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
7. 337/10 21 MASS ABDOMEN UNILATERAL- 
CYSTIC 
BENIGN SEROUS 
CYSADENOMA 
I 
8. 425/10 42 MASS ABDOMEN UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
9. 442/10 50 MASS ABDOMEN 
WITH ASCITES 
BILATERAL, 
SOLID&CYSTIC 
BILATERAL 
PAPILLARY SEROUS 
CYSTADENOCARCIN
OMA 
III 
10. 528/10 27 MASS ABDOMEN UNILATERAL –
CYSTIC 
BENIGN serous 
CYSTADENOMA 
I 
11. 589/10 40 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
12. 613/10 33 MASS ABDOMEN UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
13. 824/10 46 MASS ABDOMEN UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
14. 1001/10 42 MASS ABDOMEN R-SOLID, L-CYSTIC R-BENIGN 
BRENNER,L-BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
15. 1023/10 42 ASYMPTOMATIC UNILATERAL-
CYSTIC 
BENIGN serous 
CYSTADENOMA 
I 
16. 1025/10 23 MASS ABDOMEN UNILATERAL-
CYSTIC&SOLID 
GRANULOSA CELL 
TUMOR 
I 
17. 1031/10 32 MASS&PAIN 
ABDOMEN 
UNILATERAL-
CYSTIC 
HAEMORHAGIC 
FLUID 
CONGESTED 
SEROUS 
CYSTADENOMA 
I 
CYSTIC,HAEMO
RRHAGIC FLUID 
SEROUS 
CYSTADENOMA 
20. 1173/10 39 MASSABDOMEN 
,ASCITES 
BILATERAL,SOLI
D 
KRUKENBERG 
TUMOR 
 
21. 1181/10 25 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
22. 1314/10 34 ASYMPTOMATIC UNILATERAL-
CYSTIC 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
23. 1362/10 12 MASS ABDOMEN UNILATERAL-
SOLID,CYSTIC,V
ARIEGATED 
MIXED GERM 
CELL TUMOR 
I 
24. 1364/10 60 MASS ABDOMEN BILATERAL,CYST 
WITH 
PAPILLARY 
EXCRESCENCE 
BILATERAL 
BENIGN SEROUS 
CYSTADENOFIBR
OMA 
I 
25. 1459/10 40 MASS ABDOMEN UNILATERAL 
CYSTIC WITH 
PAPILLARY 
EXCRESCENCE 
BENIGN SEROUS 
CYSTADENOMA 
I 
26. 1553/10 70 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
27. 1606/10 22 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENFIBRO
MA 
I 
28. 1643/10 47 MASS ABDOMEN UNILATERAL-
CYSTIC,SOLID,V
ARIEGATED 
GRANULOSA CELL 
TUMOR 
I 
29. 1654/10 58 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
30. 1656/10 38 MASS ABDOMEN  UNILATERAL 
SOLID,CYSTIC,V
ARIEGATED 
GRANULOSA CELL 
TUMOR 
II 
31. 1698/10 29 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN  serous 
CYSTADENOMA 
I 
32. 1763/10 50 MASS ABDOMEN UNILATERAL,SO
LID,CYSTIC,VARI
EGATED 
GRANULOSA CELL 
TUMOR 
I 
33. 1809/10 70 MASS ABDOMEN, 
ASCITES 
BILATERAL,SOLI
D,CYSTIC,VARIE
GATED 
BILATERAL 
PAPILLARY 
SEROUS ADENO 
CARCINOMA 
II 
34. 1853/10 27 PAIN ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
35. 1892/10 24 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
36. 1894/10 28 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENGN SEROUS 
CYSTADENOMA 
I 
37. 1934/10 50 MASS ABDOMEN UNILATERAL,CY
STIC 
MATURE CYSTIC 
TERATOMA 
I 
38. 1985/10 52 MASS ABDOMEN UNILATERAL -
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
39. 2024/10 26 MASS ABDOMEN UNILATERAL -
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
40. 2050/10 50 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
41. 2107/10 23 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
42. 2119/10 29 MASS ABDOMEN UNILATERAL 
SOLID 
FIBROMA I 
43. 2124/10 40 MASS ABDOMEN UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
44. 2151/10 45 MASS ABDOMEN UNILATERAL-
CYSTIC 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
45. 2165/10 24 PAIN&MASS 
ABDOMEN 
UNILATERAL-
CYSTIC,HAEMO
RRHAGIC FLUID 
BENIGN SEROUS 
CYSTADENOMA 
I 
46. 2358/10 65 MASS ABDOMEN UNILATERAL  
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
47. 2438/10 48 MASS ABDOMEN, 
ASCITES 
BILATERAL, 
SOLID,CYSTIC, 
HAEMORHAGIC 
BILATERAL  
SEROUS ADENO 
CARCINOMA 
II 
 
48. 2499/10 50 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
49. 2605/10 35 MASS ABDOMEN UNILATERAL, 
SOLID,CYSTIC 
MUCINOUS 
CYSTADENO 
CARCINOMA 
I 
50. 2611/10 54 MASS ABDOMEN UNILATERAL  
CYSTIC 
BENIGN  SEROUS 
CYSTADENOMA 
I 
51. 2634/10 36 PAIN ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
52. 2666/10 35 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN  SEROUS 
CYSTADENOMA 
I 
53. 2722/10 40 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN  
SEROUSCYSTADE
NOMA 
I 
54. 2723/10 32 PAIN&MASS 
ABDOMEN 
UNILATERAL, 
CYSTIC, 
HAEMORHAGIC  
FLUID 
BENIGN SEROUS 
CYSTADENO 
FIBROMA. 
I 
55. 2799/10 60 MASS ABDOMEN UNILATERAL 
CYSTIC 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
56. 2906/10 63 MASS ABDOMEN UNILATERAL 
SOLID 
FIBROMA I 
57. 2911/10 21 PAIN&MASS 
ABDOMEN 
UNILATERAL –
CYSTIC 
HAEMORHAGIC 
CONGESTED 
SEROUS 
CYSTADENOMA 
I 
FLUID 
58. 3067/10 32 MASS ABDOMEN UNILATERAL-
CYSTIC 
BENIGN  
SEROUSCYSTADE
NOMA 
I 
59. 3136/10 38 MASS ABDOMEN UNILATERAL 
SOLID& CYSTIC, 
VARIEGATED 
SEROUS CYST 
ADENO 
CARCINOMA 
III 
60. 3198/10 60 MASS ABDOMEN BILATERAL,     
R& L-CYSTIC 
R- SEROUS 
CYSTADENOMA  
L-MATURE CYSTIC 
TERATOMA 
I 
61. 3223/10 26 MASS ABDOMEN UNILATERAL-
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
62. 3257/10 60 MASS ABDOMEN, 
ASCITES 
UNILATERAL, 
SOLID,CYSTIC, 
PAPILLARY 
EXCRESCENCES 
SEROUS 
CYSTADENO 
CARCINOMA 
III 
63. 3288/10 45 PAIN ABDOMEN UNILATERAL, 
CYSTIC,SOLID, 
VARIEGATED 
GRANULOSA CELL 
TUMOR 
I 
64. 3417/10 40 PAIN ABDOMEN UNILATERAL 
CYSTIC,HAEMO
RRHAGIC FLUID 
CONGESTED 
SEROUS 
CYSTADENOMA 
I 
65. 3454/10 21 PAIN ABDOMEN 
WITH ECTOPIC 
PREGNANCY 
UNILATERAL , 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
66. 3528/10 38 MASS ABDOMEN UNILATERAL-
SOLID,CYSTIC, 
VARIEGTAED 
GRANULOSA CELL 
TUMOR 
I 
67. 3529/10 48 MASS ABDOMEN, 
ASCITES 
UNILATERAL, 
SOLID , CYSTIC , 
PAPILLARY 
EXCRESCENCESS
,NECROSIS 
PAPILLARY 
SEROUS 
CYSTADENO 
CARCINOMA 
III 
68. 3544/10 26 MASS ABDOMEN UNILATERAL, 
CYSTIC 
SEROUS 
CYSTADENOMA 
I 
69. 3601/10 50 MASS ABDOMEN UNILATERAL, 
SOLID,CYSTIC,  
VARIEGATED 
GRANULOSA CELL 
TUMOR 
I 
70. 3619/10 55 MASS ABDOMEN UNILATERAL, 
SOLID,CYSTIC 
GRANULOSA CELL 
TUMOR 
I 
71. 3669/10 42 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
72. 3708/10 35 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
73. 3760/10 35 MASS ABDOMEN UNILATERAL,CY
STIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
74. 3834/10 45 MASS ABDOMEN UNILATERAL,CY BENIGN I 
STIC MUCINOUS 
CYSTADENOMA 
75. 3837/10 58 ASYMPTOMATIC UNILATERAL,CY
STIC WITH 
PAPILLARY 
EXCRESCENCESS 
BENIGN SEROUS 
ADENOFIBROMA 
I 
76. 3860/10 40 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
77. 3922/10 40 MASS ABDOMEN UNILATERAL 
CYSTIC 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
78. 3927/10 26 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
79. 3938/10 50 MASS ABDOMEN  UNILATERAL 
CYSTIC WITH 
PAPILLARY 
EXCRESCENCESS 
PAPILLARY 
SEROUUS 
CYSTADENO 
FIBROMA 
I 
80. 3945/10 28 MASS ABDOMEN UNILATERAL 
CYSTIC 
PAPILLARY 
EXCRESCENCESS 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
81. 4005/10 28 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
 
I 
82. 
 
4183/10 30 MASS ABDOMEN UNILATERAL, 
CYSTIC 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
83. 4247/10 37 MASS ABDOMEN UNILATERAL 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
84. 4275/10 27 MASS ABDOMEN UNILATERAL 
SOLID AND 
CYSTIC 
MUCINOUS 
CYSTADENO 
CARCINOMA 
I 
85. 4352/10 28 MASS ABDOMEN UNILATERAL, 
CYSTIC 
 MUCINOUS 
CYSTADENOMA 
I 
86. 4473/10 23 MASS ABDOMEN UNILATERAL, 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
87. 133/11 22 MASS ABDOMEN UNILATERAL 
CYSTIC 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
88. 181/11 50 MASS ABDOMEN UNILATERAL,SO
LID, CYSTIC 
SEROUS 
CYSTADENOCARC
INOMA 
II 
89. 294/11 45 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
90. 369/11 19 PAIN ABDOMEN UNILATERAL BENIGN I 
CYSTIC,HAEMO
RRHAGIC FLUID 
MUCINOUS 
CYSTADENOMA  
91. 493/11 21 PAIN ABDOMEN UNILATERAL, 
CYSTIC,HAEMO
RRHAGIC FLUID 
BENIGN SEROUS 
CYST 
I 
92. 604/11 27 PREGNANCY 
ASSOCIATED 
UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
93. 642/11 45 MASS ABDOMEN UNILATERAL , 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
94. 644/11 30 MASS ABDOMEN UNILATERAL 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
95. 700/11 32 MASS ABDOMEN UNILATERAL, 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
96. 758/11 35 MASS ABDOMEN UNILATERAL, 
CYSTIC WITH 
PAPILLARY 
EXCRESCENCESS 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
97. 760/11 50 MASSABDOMEN 
,ASCITES 
UNILATERAL 
SOLID AND 
CYSTIC 
MUCINOUS 
CYSTADENO 
CARCINOMA 
I 
98. 1023/11 26 ASYMPTOMATIC UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
99. 1035/11 31 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
100. 1217/11 47 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
101. 1381/11 50 MASS ABDOMEN BILATERAL 
SOLID 
BILATERAL 
KRUKENBERG 
TUMOR 
 
102. 1481/11 50 MASS ABDOMEN UNILATERAL, 
SOLID,CYSTIC 
PAPILLARY 
SEROUS 
CYSTADENO 
CARCINOMA 
III 
103. 1495/11 19 PREGNANCY 
ASSOCIATED 
UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
104. 1667/11 16 MASS ABDOMEN UNILATERAL 
CYSTIC WITH 
PAPILLARY 
EXCRESCENCESS 
BORDERLINE 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBRMA 
I 
 
 
105. 1682/11 38 MASS  ABDOMEN UNILATERAL 
CYSTIC 
,PAPILLARY 
EXCRESCENCESS 
 PAPILLARY 
SEROUS 
CYSTADENOFIBR
OMA 
I 
106 1872/11 26 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
107. 2082/11 55 MASS ABDOMEN UNILATERAL,CY MUCINOUS I 
STIC CYSTADENOMA 
108. 2112/11 50 MASS ABDOMEN UNILATERAL 
CYSTIC 
BORDERLINE 
MUCIONUS 
CYSTADENOMA 
I 
109. 2134/11 22 PREGNANCY 
ASSOCIATED 
UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
110. 2364/11 60 ASYMPTOMATIC UNILATERAL, 
CYSTIC 
BENIGNSEROUS 
CYSTADENOMA 
I 
111. 2439/11 47 MASS ABDOMEN UNILATERAL, 
SOLID , CYSTIC, 
VARIEGATED 
GRANULOSA CELL 
TUMOR 
I 
112. 2593/11 25 MASS ABDOMEN UNILATERAL, 
CYSTIC 
 MUCINOUS 
CYSTADENOMA 
I 
113. 2810/11 25 MASS ABDOMEN UNILATERAL, 
CYSTIC, 
PAPILLARY 
EXCRESCENCESS 
SEROUS 
CYSTADNO 
FIBROM 
 
I 
114. 2897/11 38 MASS ABDOMEN UNILATERAL, 
CYSTIC 
 MUCINOUS 
CYSTADENOMA 
I 
115. 2985/11 52 MASS ABDOMEN UNILATERAL, 
SOLID 
MALIGNANT 
SEROUS 
CYSTADENO 
CARCINOMA 
III 
116. 3080/11 35 MASS ABDOMEN UNILATERAL 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
117. 3391/11 44 MASS ABDOMEN UNILATERAL 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
118. 3427/11 25 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERAOMA 
I 
119. 3480/11 45 MASS ABDOMEN UNILATERAL 
SOLID  
FIBROMA I 
120. 3622/11 21 MASS ABDOMEN UNILATERAL 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
121. 3624/11 35 MASS ABDOMEN UNILATERAL, 
SOLID,CYSTIC 
MUCINOUS 
CYSTADENO 
CARCINOMA 
I 
122. 3627/11 45 MASS ABDOMEN UNLAERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
123. 3684/11 25 MASS  ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
124. 3685/11 60 MASS ABDOMEN BILATERAL 
CYSTIC, 
PAPILLARY 
EXCRESCENCESS 
B/L BORDERLINE 
SEROUS 
CYSTADENO 
FIBROMA 
I 
125. 3763/11 25 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BORDERLINE 
SEROUSTUMOR 
I 
126. 3971/11 42 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
I 
CYSTADENOMA 
127. 4048/11 22 ASYMPTOMATIC UNILATERAL, 
CYSTIC 
PAPILLARY 
SEROUS 
CYSTADENO 
FIBROMA 
I 
128. 4203/11 55 ASYMPTOMATIC, UNILATERAL, 
SOILD &CYSTIC 
METASTATIC 
ADENO 
CARCINOMATOU
S DEPOSITS 
- 
129. 4239/11 27 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
130. 4345/11 40 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
131. 4488/11 45 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
132. 4489/11 27 MASS ABDOMEN UNILATERAL 
,CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
133. 4508/11 34 MASS ABDOMEN BILATERAL, 
CYSTIC, 
PAPILLARY 
EXCRESCENCESS 
BILATERAL 
PAPILLARY 
CYSTADENO 
FIBROMA 
I 
134. 4544/11
1 
25 MASS ABDOMEN UNILATERAL 
CYSTIC 
MATURE CYSTIC 
TERATOMA 
I 
135. 4564/11 50 MASS ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
136. 4689/11 45 MASS ABDOMEN UNILATERAL, 
SOLID 
FIBROTHECOMA I 
137. 4758/11 43 MASS ABDOMEN BILATERAL 
CYSTIC 
BILATERAL 
MATURE CYSTIC 
TERATOMA 
I 
138. 35/12 45 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENOMA 
I 
139. 48/12 35 MASS ABDOMEN UNILATERAL 
CYSTIC 
PAPILLARY 
SEROUS 
CYTSADENO 
FIBROMA 
I 
140. 97/12 49 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN SEROUS 
CYSTADENO 
FIBROMA 
I 
141. 343/12 50 MASS 
ABDOMEN,ASCIT
ES 
BILATERAL 
SOLID,CYSTIC 
B/L  SEROUS 
CYSTADENO 
CARCINOMA 
III 
142. 800/12 25 MAS S ABDOMEN UNILATERAL, 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
143. 921/12 45 MASS ABDOMEN BILATERAL, 
SOLID 
BILATERAL 
KRUKENBERG  
 
144. 1131/12 55 MASS ABDOMEN UNILATERAL, 
SOLID AND 
BENIGN 
MUCINOUS AND 
I 
CYSTIC BENIGN BRENNER  
145. 1371/12 45 MASS ABDOMEN UNILATERAL, 
CYSTIC 
MUCINOUS 
CYSTADENOMA 
I 
146. 1376/12 55 ASYMPTOMATIC UNILATERAL, 
SOLID 
BENIGN BRENNER 
TUMOR 
I 
147. 1693/12 32 MASS ABDOMEN UNILATERAL, 
CYSTIC ,FOCAL 
SOLID 
BORDERLINE 
MUCINOUS 
CYSTADENOMA 
I 
148. 1869/12 16 MASS ABDOMEN UNILATERAL 
CYSTIC 
BENIGN 
MUCINOUS 
CYSTADENOMA 
I 
149. 1870/12 58 MASS ABDOMEN UNILATERAL 
CYSTIC 
BORDERLINE  
MUCINOUS 
CYSTADENOMA  
I 
150. 2121/12 20 PAIN & MASS 
ABDOMEN 
UNILATERAL, 
SOLID 
DYSGERMINOMA I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
OBSERRVATION AND RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
Thisprospective study covered a total number of 150 ovarian neoplasms referred 
from Raja Mirasudhar Government hospital(RMH),Thanjavur Medical college 
during the study period from 2010 to  May 2012. 
We received bilateral,unilateral salphingo-oophorectomy along with total 
abdominal hysterectomy and ovariatomy specimens. Specimens were fixed in to 
in neutral buffered formalin and processed routinely. 
I: INCIDENCE: 
          The following table (table 3) shows the total number of ovarian  
neoplasms among female neoplasms. 
TABLE 3: TOTAL NUMBER OF OVARIAN NEOPLASMS IN 
RELATION TO TOTAL FEMALE NEOPLASMS. 
SL.NO PERIOD TOTAL NO 
OF FEMALE 
NEOPLASMS 
TOTAL NO OF 
OVARIAN 
NEOPLASMS 
% 
1. Jan10-May10 396 32 8.08% 
2. Jun10-Dec10 424 36 8.4% 
3. Jan11-May11 389 26 6.6% 
4. May11-Dec11 422 33 7.8% 
5. Jan12-May12 289 23 7.9% 
 Total 1920 150 7.8% 
 
The  average incidence of ovarian neoplasms(including benign  and  
malignant) among females is  7.8%.  [CHART 1]. 
 II. AGE  INCIDENCE : 
In this study ovarian neoplasms were in the age group ranging from   10 
to 79 years. The patients were divided into 7 groups according to their age(i.e, 
10-19 yrs,20-29 yrs,30-39 yrs,40-49 yrs, 50-59 yrs,60-69 yrs and 70-79 yrs), 
Age incidence of ovarian neoplasms is shown in the following   Table 4. 
TABLE 4: AGE INCIDENCE OF OVARIAN NEOPLASMS 
SL.NO AGE IN YEARS TOTAL NO.OF CASES % 
1 10-19 5 3.3 % 
2 20-29 44 29.3 % 
3 30-39 29 19.3 % 
4 40-49 37 24.6 % 
5 50-59 25 16.6 % 
6 60-69 8 5.3 % 
7 70-79 2 1.3 % 
 TOTAL 150  
 
From the above table it is evident that the highest incidence of ovarian 
neoplasms is seen in the age group between 20-29 yrs and the lowest 
incidence is after 70 yrs of age.[CHART2] 
 
 
 
 
CHART 1: COMPARISON OF OVARIAN NEOPLASMS IN RELATION TO TOTAL OVARIAN 
NEOPLASMS 
 
 
CHART 2: AGE INCIDENCE OF OVARIAN NEOPLASMS 
 
 
 
1920 
150 
Total No.of female neoplasms Total No.of ovarian neoplasms
0
500
1000
1500
2000
2500
To
ta
l N
o
. o
f 
n
e
o
p
la
sm
s 
0
5
10
15
20
25
30
20-29 30-39 40-49
29 
19 
24 p
e
rc
e
n
ta
ge
 
Age in yrs 
20-29
30-39
40-49
III. AGE INCIDENCE OF CATEGORIES OF OVARIAN  NEOPLASMS 
: 
The ovarian neoplasms are divided into Benign, Borderline, Malignant 
categories as given in the  following table.5 
TABLE 5: 
SL.NO AGE – YEARS BENIGN BORDERLINE MALIGNANT 
1 10-19 3 1 1 
2 20-29 40 1 3 
3 30-39 19 2 8 
4 40-49 28 3 6 
5 50-59 11 3 11 
6 60-69 5 2 1 
7 70-79 1 - 1 
 TOTAL 109 
(72.6%) 
12 
(8%) 
29 
(19.3%) 
 
 From the above table.5, it is evident that the highest incidence of benign 
neoplasms is seen in 20-29 yrs(40/109 cases,37%), borderline neoplasm in 40-
49 yrs (3/109 cases,25%) and malignant neoplasm in 50-59 yrs ( 11 /29cases, 
52%). [CHART 3] 
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TABLE 5A:   FREQUENCY DISTRIBUTION OF INDIVIDUAL BENIGN 
TUMORS IN DIFFERENT  AGE  GROUPS. 
Diagnosis Age 
10-19 
yrs 
Age  
20-29 
yrs 
Age 
30-39 
yrs 
Age 
40-49 
yrs 
Age 
50-59 
yrs 
>60 
Yrs 
Total(%)  
Serous 
cystadenoma 
- 11 5 8 2 2 28 
(25.6%) 
Serous 
cystadenofibroma 
- 4 5 7 2 2 20 
(18.3%) 
Mucinous 
cystadenoma 
1 9 10 10 1 1 32 
(29.3%) 
Benign Brenner - - - 1 2 - 3 
(2.75%) 
Fibroma  - 1 - 1 - 1 3 
(2.75%) 
Mature cystic 
teratoma 
- 10 4 5 3 - 22 
(20.1%) 
Fibrothecoma  - - - 1 - - 1 
(0.9%) 
Total  1 35 24 33 10 6 109 
(100%) 
 
 
 
 
TABLE 5B: FREQUENCY DISTRIBUTION OF INDIVIDUAL 
MALIGNANT TUMORS IN DIFFERENT AGE GROUPS 
Diagnosis Age 
10-19 
yrs 
Age 
20-29 
yrs 
Age 
30-39 
yrs 
Age 
40-49 
yrs 
Age 
50-59 
yrs 
Age 
>60 
yrs. 
Total% 
 Papillary Serous 
cystadenocarcinoma 
- - 1 2 5 2 10(34.4%) 
Mucinous 
cystadenocarcinoma 
- 1 2 - 1 - 4(13.6%) 
Granulosa cell 
tumor 
- 1 2 3 3 - 9(31.2%) 
Dysgerminoma  - 1 - - - - 1(3.4%) 
Mixed germ cell 
tumor 
1 - - - - - 1(3.4%) 
Metastatic 
adeno/krukenberg 
- - 1 1 2 - 4(13.6%) 
Total  1 3 6 6 11 2 29(100%) 
 
Of all patients with serous carcinomas(figure2)  50 %(5/10 cases)  
patients were in the age group of  50-59 yrs,  20 %(2/10 cases) were in the 
agegroup of 40-49 and 60-69 yrs. 4 patients had mucinous cystadenocarcinoma 
(figure 3)among which  50 % (2/4 cases) are in30-39 yrs and Metastatic tumors 
predominates after the age of 50 yrs.    
 
 
 
IV. CLINICAL EVALUATION: 
                     All the cases were evaluated clinically at the time of admission  
as in the following table 6. 
TABLE 6:  CLINICAL FEATURES OF VARIOUS OVARIAN TUMORS 
SL.NO CLINICAL FEATURES NO.OF CASES % 
1. Mass abdomen 119 79.3 % 
2. Pain abdomen 11 7.3 % 
3. Pregnancy associated 4 2.6 % 
4. Ascites 7 4.6 % 
5. Asymptomatic 9 6 % 
 
 Abdominal mass is the most common clinical Presentation (119 
cases,79.3%) followed by abdominal pain(11 cases,7.3%)  Four cases were 
found to be associated with pregnancy.  Nine  cases were asymptomatic and 
detected during  abdominal  ultrasonography  done for other causes(CHART 4) 
 
 
 
 
 
 
CHART 4: PIE CHART DEPICTING THE PERCENTAGE OF SIGNS ANDSYMPTOMS AMONG OVARIAN 
TUMOR PATIENTS. 
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V. LATERALITY: 
              Likewise tumors are also categorised as with unilateral/bilateral  
ovarian involvement as in the given table.7 . 
TABLE 7: DISTRIBUTION OF OVARIAN TUMORS IN RELATION TO  
LATERALITY OF INVOLVEMENT. 
 
L.NO TUMORS UNILATERAL % BILATERAL % 
1. SEROUS 
Benign 
Borderline 
Malignant 
 
44 
2 
6 
  
4 
1 
4 
 
 TOTAL 52 38.2% 9 65% 
2 MUCINOUS 
Benign 
Borderline 
Malignant 
 
31 
9 
4 
  
1 
- 
- 
 
 TOTAL 44 32.3% 1 7% 
3. TRANSITIONAL 3  -  
4. SEXCORD-
STROMAL 
13  -  
5. GERM CELL 
TUMOR 
23 23% 1 7% 
6. METASTATIC 1  -  
7. KRUKENBERG   3 21% 
 Grand Total 136  14  
The above table .7, shows that  among  serous tumors 52/61 cases,(85  
  
 
 
 
CHART 5: DISTRIBUTION OF OVARIAN TUMORS IN RELATION TO LATERALITY OF 
INVOLVEMENT 
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 % ) were unilateral at the time of presentation and 9/61,( 14.7%) cases were  
bilateral.  Among  mucinous tumors (figure 4,10,11),44/45 cases,(97.7 %  ) 
were unilateral and  1/45(2.2%)  cases were bilateral. Among  germ cell  
tumors, 23/24 cases(98.9 %) were  unilateral and 1/24 (4.1%) cases were 
bilateral.  Most of the  Metastatic   tumors(fig.6,18,19) ,3/4 cases,(75 %)  were 
bilateral at the time of presentation. 
              Bilateral ovarian tumors were seen in 14 cases.  Bilaterality  was 
more a feature of malignant tumors. 31% (9/29) of malignant tumors were  
bilateral whereas only 4.5%(5/109) benign tumors were bilateral. Among  
malignant tumors 50% serous carcinomas(figure8,9) are bilateral followed by  
metastatic tumors (75%.)  None of the mucinous  cystadenocarcinomas 
(figure25)were bilateral. (CHART5) 
 
VI. GROSS MORPHOLOGY OF OVARIAN NEOPLASMS : 
The ovarian neoplasms were divided into following types according to  
gross morphology as shown in following table.8. 
 
 
 
 
  
CHART 6: GROSS MORPHOLOGY OF OVARIAN TUMORS 
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Gross Histomorphology 
pure cystic
pure solid
mixed solid &cystic
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cyst with sebaceous
material,hair
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 TABLE 8:GROSS MORPHOLOGY OF OVARAIN NEOPLASMS: 
SL.NO GROSS MORPHOLOGY NUMBER OF CASES(%) 
1. Pure solid 9 (6%) 
2. Pure cystic 71 (47.3%) 
3. Mixed solid & cystic 18 (12%) 
4. Cystic with papillary excrescencess 12(8%) 
5. Solid with variegated appearance 9(6%) 
6. Cysts with haemorrhagic fluid 9(6%) 
7. Cyst with sebaceous material&hair. 22(14%) 
 TOTAL 150 (100%) 
 
Most common presentation of ovarian tumors  in this study  as shown in  
the above table.8. is purely cystic masses ( 71 cases,47%). Followed by  cysts 
with sebaceous material and hair(22 cases, 14%) and  Mixed solid and cystic 
tumors( 18 cases,12%). Least common presentation is  purely  solid  
tumors(6%). [CHART6]. 
 
 
 
 
 
VII :  DISTRIBUTION OF OVARIAN NEOPLASMS ACCORDING TO 
HISTOLOGICAL CLASSIFICATION.TABLE 9: 
SL.NO CLASSIFICATION NO.OF 
CASES 
TOTAL 
CASES 
% 
1. SURFACE EPITHELIAL 
TUMOR  
Benign 
Borderline  
Malignant  
 
 
83 
12 
14 
 
 
 
109 
 
 
 
72.6% 
 
2. GERM CELL TUMOR 
Benign 
Malignant 
 
22 
2 
 
 
24 
 
 
16% 
3. SEXCORD-STROMAL 
TUMOR 
Benign 
Malignant 
 
 
4 
9 
 
 
13 
 
 
8.6% 
4. METASTATIC 4 4 2.6% 
 Total 150 150  
 
It is evident from the above table .9. that ,of the  total 150 neoplasms ,  
surface epithelial tumors predominates  with 109 cases(72.6%),followed by 
germ cell tumors with 24 cases(16%) and sex cord – stromal tumors (13 
cases,8.6%).[CHART7]. 
 
 
  
 
CHART 7: INCIDENCE OF HISTOLOGICAL TYPES OF OVARIAN NEOPLASMS IN RELATION TO 
TOTAL OVARIAN NEOPLASMS 
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CHART 8: INCIDENCE OF HISTILOGICAL SUBTYPES OF SURFACE EPITHELIAL TUMORS 
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III:SUBCLASSIFICATION OF SURFACE EPITHELIAL TUMORS: 
Surfac  epithelial tumors are classified according to WHO HISTOLOGICAL 
CLASSIFICATION  and is given in the following table 10. 
TABLE 10: 
SL.NO CLASSIFICATION NO.OF 
CASES 
% AVERAGE 
1. SEROUS TUMORS 
Benign  
Borderline  
Malignant  
 
48 
3 
10 
 
78.6 % 
4.9% 
16.3 % 
 
 
55.9% 
 TOTAL 61   
2. MUCINOUS 
Benign  
Borderline  
Malignant  
 
32 
9 
4 
 
71.1 % 
20 % 
8.8 % 
 
 
41.2% 
 TOTAL 45   
3. TRANSITIONAL 
Benign Brenner 
 
3 
 
3% 
 
3.3% 
 Grand total 109   
 
  From the above table.10, it is evident that  among all  surface epithelial 
tumors,   Serous  tumors predominates (61cases,55.9 %) followed by mucinous 
tumors (45cases, 41 %) and 3 cases of transitional tumor (figure4,12) were also 
observed.[CHART8]. 
 
IX :  HISTOMORPHOLOGICAL FEATURES OF BORDERLINE 
SURFACE EPITHELIAL TUMORS:TABLE 11: 
SL.NO HISTOLOGICAL FEATURE NO.OF CASES 
 
 
 
 
 
 
 1.SEROUS 
BORDERLINE 
 
Histology: 
1.Typical 
2.Micropapillary  
 
3 
0 
Laterality: 
1.Unilateral  
2.Bilateral 
 
2 
1 
Surface involvement 
1.Present  
2. Absent 
 
0 
3 
Microinvasion 
1.Present 
2.Absent 
 
0 
3 
 
2.MUCINOUS 
BORDERLINE 
Histology: 
1.Intestinal 
2.Endocervical 
 
9 
0 
 
The above table. 11, shows that all cases of borderline serous 
tumors(figure1,7,22) showed a typical hierrarchial branching pattern of papillae 
(3cases,100%) . At the time of presentation ,2 cases were unilateral and 1 case 
was bilateral. None of the three cases showed  surface involvement nor 
microinvasion. Table also shows that all mucinous borderline tumors (figure24) 
, 4/4 cases,(100%)  were of Intestinal type.  
  
X: HISTOMORPHOLOGY OF MALIGNANT SURFACE EPITHELIAL 
TUMOR:TABLE  12: 
SL.NO HISTOLOGICAL TYPE NO.OF CASES 
1. SEROUS-GRADING 
1.LOW GRADE 
2.HIGH GRADE 
 
4 
6 
 TOTAL 10 
2. MUCINOUS 
TYPE OF INVASION 
1.EXPANSILE 
2.INFILTRATING 
 
 
4 
0 
 TOTAL 4 
 
Malignant serous tumors are graded according to recent 2-tier system of 
classification. Above  table. 12, shows that , 4/10 cases(40%) were low grade 
carcinomas and 6/10 cases(60%) were high grade.  High grade serous 
carcinomas are common among all serous carcinomas. All 4 cases of mucinous 
carcinomas showed  expansile type of  invasion.  
 
 
 
  
 
 
XI.SEX CORD STROMAL CELL TUMORS: 
Sex cord –stromal tumors  were  sub-classified and their individual  
incidence is given in the  following table .13. 
 
TABLE 13: 
SL.NO CLASSIFICATION NO.OF CASES % 
1. Granulosa cell tumor 
1.adult type 
2. juvenile type 
 
9 
0 
 
69 % 
2. Fibroma 3 23 % 
3. Fibrothecoma 1 8 % 
 Total 13  
 
The above table.13, shows that,among  sex cord stromal cell tumors  
group , granulosa cell tumor (figure13)   predominates( 9 cases, 69%)  followed 
by  fibroma (figure15) (3cases,23%) and    fibrothecoma(figure14) (1 case,8%). 
[CHART 9] 
 
 
  
 
 
 
 
CHART 9: INCIDENCE OF SUBTYPES OF SEX CORD- STROMAL TUMORS 
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XII :  GERM CELL TUMORS: 
                   Germ cell tumors were subclassified  and their individual tumor 
incidence is given in the following table.14 
 
TABLE 14: 
SL.NO CLASSIFICATION NO.OF CASES % 
1. Teratoma 
1.Benign 
2.Malignant 
 
22 
 
91.6% 
2. Dysgerminoma 1 4.1% 
3. Mixed germ cell tumor 1 4.1% 
 Total 24  
 
From the above table .14, it is evident that among  Germ cell tumor 
group,  Mature cystic teratomas  predominates( 22 cases,91%) followed by 
Dysgerminoma (figure5,16) ( 1 case,4%) and Mixed germ cell tumor (figure17) 
(1 case, 4%).CHART10. 
 
 
 
 
  
 
CHART 10: INCIDENCE OF SUBTYPES OF GERM CELL TUMORS 
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XIII: IMMUNOHISTOCHEMISTRY: KI-67 LABELLING INDEX 
TABLE  15:A 
SL.NO HPE.NO HPE.DIAGNOSIS Ki-67(LI) 
1. 1667/11 Borderline serous tumor 24% 
2. 3685/11 Borderline serous tumor 19% 
3. 3763/11 Borderline serous tumor 26% 
4. 1096/10 Borderline mucinous tumor 28% 
5. 1314/10 Borderline mucinous tumor 24% 
6. 2151/10 Borderline mucinous tumor 26% 
7. 2499/10 Borderline mucinous tumor 30% 
8. 2799/10 Borderline mucinous tumor 18% 
9. 294/11 Borderline mucinous tumor 23% 
10. 2112/11 Borderline mucinous tumor 29% 
11. 1693/12 Borderline mucinous tumor 31% 
12. 1870/12 Borderline mucinous tumor 23% 
13. 442/10 High grade serous Carcinoma 52% 
14. 1809/10 High grade serous Carcinoma 47% 
15. 2438/10 High grade serous Carcinoma 44% 
16. 3136/10 Low  grade serous Carcinoma 43% 
17. 3257/10 Low  grade serous Carcinoma 39% 
18. 3529/10 High grade serous Carcinoma 42% 
19. 181/11 Low grade serous Carcinoma 33% 
20. 1481/11 High grade serous Carcinoma 46% 
21. 2985/11 Low  grade serous Carcinoma 41% 
22. 343/12 High grade serous Carcinoma 48% 
23. 2605/10 Mucinous Carcinoma 38% 
24. 4275/10 Mucinous carcinoma 36% 
25. 760/11 Mucinous carcinoma 42% 
26. 3624/11 Mucinous carcinoma 40% 
 
ki-67 labelling index was done in all 12 cases of borderline tumors and 14 
cases of malignant tumors of epithelial origin. Diffuse intense nuclear staining 
is considered as positive and weak cytoplasmic staining is considered as  
negative. 
 
 
 
 
 
 
 
 
 
TABLE 15 B: p53 IMMUNOHISTOCHEMISTRY 
SL.NO HPE NO HPE DIAGNOSIS  p53 IHC 
1. 442/10 High grade serous Carcinoma Positive  
2. 1809/10 High grade serous Carcinoma Positive  
3. 2438/10 High grade serous Carcinoma Positive  
4. 3136/10 Low  grade serous Carcinoma Positive  
5. 3257/10 Low  grade serous Carcinoma Positive  
6. 3529/10 High grade serous Carcinoma Positive  
7. 181/11 Low grade serous Carcinoma Negative  
8. 1481/11 High grade serous Carcinoma Negative  
9. 2985/11 Low  grade serous Carcinoma Positive  
10. 343/12 High grade serous Carcinoma Negative  
11. 2605/10 Mucinous Carcinoma Negative 
12. 4275/10 Mucinous carcinoma Negative 
13. 760/11 Mucinous carcinoma Negative  
14. 3624/11 Mucinous carcinoma Negative  
 
P53 immunohistochemical staining was applied to all (14) cases of 
malignant tumors of surface epithelial origin like serous carcinomas including 
low and high grade and mucinous carcinomas. Results were interpreted as 
Positive when cells shows diffuse and intense nuclear staining. 
 
 
 
 
XIV:  P53 EXPRESSION IN TYPE I  AND  TYPE II SURFACE 
EPITHELIAL TUMORS  OVARY:TABLE  16: 
Type of ovarian tumor P53expression 
Positive    
P53expression  
Negative 
Total  
TypeI  Low grade serous 
Carcinoma 
1(25%) 
 
3(75%) 4 
Type 
II  
High grade serous 
carcinoma 
5(83.3%) 1(16.7%) 6 
 
The above table.16  shows that  about 3 cases(75%)  of low grade serous 
carcinoma belonging to  type I pathway of  tumorigenesis, showed negative for 
p53  immunohistochemical  staining (figure 21). Whereasabout  5 cases (83%) 
of  high grade serous carcinoma which are included in the type II pathway of  
tumorigenesis showed positivity for p53 staining. (figure 20) 
XV:  Ki -67  EXPRESSION IN SEROUS TUMORS:TABLE 17: 
Sl.no HPE 
DIAGNOSIS 
0-25 26-50 51-75 76-100 Total  
1. Serous 
Borderline 
2(66.7%) 1(33.3%) - - 3 
2. Serous 
Malignant 
- 9(90%) 1(10%) - 10 
 
There are three serous borderline tumors in total. From the above table. 
17 it is evident that each one of them had a different level of expression of ki-67 
labelling index.  One case  showed  a ki-67 LI  of 24%,  second  tumorshowed 
ki-67 LI of 19%(figure 22), and the third  case  showed a ki-67 LI  of26% and 
this was found to be the  greatest level of expression among all serous 
borderline tumors.  
The above table.17   also shows that there are about 10 cases of serous 
carcinomas(figure23)  of  which 9 cases showed ki-67 LI  between 26-50 and 1 
case showed ki-67 LI above 50. Highest level of ki-67  LI  was found to be in 
high grade serous carcinomas.  Among  all  high  grade(6/10)  serous 
carcinoma, highest  ki-67  LI  was found to be 52%  and lowest  value among 
high grade tumors was 42%. Among the four low grade tumors highest ki-67 
expression was 43%  and the least value was found to be 39%.   
XVI: KI-67 EXPRESSION IN MUCINOUS TUMORSTABLE 18: 
Sl.no HPE 
Diagnosis 
0-25 26-50 51-75 76-100 Total  
1. Mucinous 
Borderline 
4(44.4%) 5(55.5%) - - 9 
2. Mucinous 
carcinoma 
- 4 - - 4 
 
There were about nine mucinous borderline tumors (figure24). The above 
table.18  shows that  ki-67 LI  in  4 cases , 44%  of mucinous borderline tumors 
was between 0-25  and  5 cases ,55%  showed ki-67 LI between  26-50.  Among 
them highest level of ki-67 expression found was 30% and the least  ki-67 LI 
was 23%. The above table.18 also shows that   there were about 4  cases of  
mucinous carcinomas (figure 25),  all 4 showed ki-67 LI  was between 26-50.  
Of  them the highest level of Ki-67was 40% and least value was 36%.  
The immunostaining pattern was heterogenous throughout the tumor and 
evaluation was done in most positively stained areas.The mean ki-67 LI in 
borderline tumors was 25% (19-31%). Mean ki-67 LI in malignant tumors was 
42% (33-52%). When compared with the borderline tumors ,ki-67 LI was found 
to be statistically significant increase in malignant tumors(p<0.005).In 
malignant group of tumors, Serous carcinomas(figure23) showed high index of  
52%, followed by Mucinous carcinomas (figure 25) with a mean index of 39%.                 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 1 : BILATERAL BORDERLINE SEROUS CYSTADENOMA. CUT SURFACE- MULTILOCULATED 
CYSTS  WITH NUMEROUS TINY  PAPILLARY EXCRESCENSESS . 
 
FIGURE 2:  BILATERAL PAPILLARY SEROUS CYSTADENOCARCINOMA WITH SOLID AND CYSTIC AREAS 
WITH OMENTAL DEPOSITS(ARROW). 
  
FIGURE 3 : MUCINOUS CYSTADENOCARCINOMA. CUT SURFACE- SHOWS MULTILOCULATED CYST 
FILLED WITH MUCIN AND FOCAL SOLID AREAS. 
 
FIGURE 4: MUCINOUS CYSTADENOMA WITH BRENNER TUMOR.CUT SURFACE-MULTILOCULATED 
CYSTS  FILLED  WITH MUCIN AND FOCAL YELLOW SOLID AREA MEASURING 2X2CM.(BRENNER). 
 FIGURE 5 : DYSGERMINOMA.CUT SURFACE SHOWS SOLID HOMOGENOUS,FIRM,LOBULATED GREY 
TAN  MASS. 
 
 
FIGURE 6: KRUKENBERG TUMOR.TYPICALLY INVOLOVEMENT IS BILATERAL& ARE CHARACTERISED BY 
MULTINODULAR EXTERNAL SURFACE. 
 
 
 FIGURE 7: SEROUS BORDERLINE TUMOR WITH PAILLARY FRONDS LINED BY CELLS WITH MILD TO 
MODERATE ATYPIA WITHOUT STROMAL INVASION.( H&E-10X). 
 
 
FIGURE 8: LOW GRADE SEROUS CARCINOMA SHOWING  BROAD PAPPILLARY FRONDS LINED BY 
CELLS WITH MILD TO MODERATE ATYPIA (H&E-10X). 
 
 
  
 
FIGURE 9A:  HIGH GRADE SEROUS CARCINOMA WITH  SOLID PROLIFERATION OF TUMOR CELLS AND   
FOCAL  GLANDULAR ARCHITECTURE (ARROW) (H&E- 10X) 
 
 
FIGURE 9B: HIGH GRADE SEROUS CARCINOMA- CLOSELY PACKED PAPILLAE WITHOUT FIBROUS CORE 
AND CELLS SHOW MARKED NUCLEAR ATYPIA AND PROMINENT NUCLEOLI WITH INCRASED MITOSIS 
(H&E - 45X). 
 
  
FIGURE 10A : MUCINOUS BORDERLINE TUMOR- SHOWING PAPILLARY FRONDS LINED BY MUCIN 
CONTAINING COLUMNAR EPITHELIUM WITH GOBLET CELLS- INTESTINAL TYPE (H&E- 10X) 
 
 
FIGURE 10 B : MUCINOUS BORDERLINE TUMOR –INTESTINAL TYPE.HIGH POWER VIEW SHOWING  
GOBLET CELLS (H&E- 45X) 
 
 
 
  
 
FIGURE 11 A: MUCINOUS CARCINOMA SHOWING EXPANSILE INVASION – CLOSELY PACKED(BACK-
BACK) GLANDS WITH LITTLE/NO STROMAL SUPPORT (H&E- 10X) 
 
 
FIGURE 11 B : HIGH POWER VIEW : TUMOR CELLS SHOWING STRATIFICATION(>3LAYERS) OF NUCLEI 
WITH MITOTIC ACTIVITY (SMALL ARROW) (H&E- 45X). 
 FIGURE 12 : MUCINOUS CYSTADENOMA WITH BENIGN BRENNER COMPONENT- SHOWING 
GLANDS LINED BY MUCIN CONTAINING COLUMNAR EPITHELIUM WITH NESTS(ARROW 
HEAD)  OF TRANSITIONAL EPITHELIAL CELLS (H&E- 10x) 
 
FIGURE 13 A:  WELL DIFFERENTIATED GRANULOSA CELL TUMOR WITH, MICROFOLLICULAR PATTERN 
(H&E- 10X) 
 
 FIGURE 13 B:  HIGH POWER VIEW SHOWING  NUMEROUS CALL- EXNER BODIES CONTAINING 
HYALINE MATERIAL (H&E- 45X). 
 
 
FIGURE 14: FIBROTHECOMA SHOWING FASCICLES OF SPINDLE CELLS  ADMIXED WITH NUMEROUS 
LUTENISED  CELLS (ARROW) WITH PALE VACUOLATED CYTOPLASM.(H&E-10X). 
 
 FIGURE 15:  OVARIAN FIBROMA SHOWING, SPINDLE CELLS ARRANGED IN STORIFORM PATTERN  
WITH BLAND NUCLEAR FEATURES(10X). 
 
 
FIGURE 16: DYSGERMINOMA.IRREGULAR ISLANDS OF CELLS SEPARATED BY FIBROUS SEPTA(ARROW) 
INFILTRATED WITH LYMPHOCYTES.  (H&E- 10X). 
 
 
 
 Figure17A :MIXED GERM CELL TUMOR, EXHIBITING YOLK SAC COMPONENT, FESTOON 
PATTERNENDODERMAL SINUS IS SEEN ( H&E- 10x). 
 
 
FIGURE 17 B: HIGH POWER VIEW SHOWING SCHILLER-DUVAL BODIES .(H&E- 45x). 
 
 
 
 
  
FIGURE 18: METASTATIC ADENOCARCINOMATOUS DEPOSITS . MALIGNANT GLANDS LINED BY  
ATYPICAL COLUMNAR EPITHELIUM WITH  LUMINAL AND INTRACYTOPLASMIC MUCIN RESEMBLING 
GIT  EPITHELIUM INFILTRATING INTO OVARIAN STROMA (H&E - 10X). 
 
 
FIGURE 19: KRUKENBERG TUMOR - SHOWING SIGNET RING CELLS (H&E- 10X) 
 
 
 
 
 Figure 20:  HIGH GRADE SEROUS CARCINOMA- DIFFUSE p53  NUCLEAR STAINING(10X). 
 
 
FIGURE  21:  LOW GRADE SEROUS CARCINOMA – NEGATIVE STAINING FOR  p53 (10X). 
 
 
  
FIGURE 22: SEROUS BORDERLINE  TUMOR –Ki 67 LI –19% (45X). 
 
 
FIGURE  23:  SEROUS CARCINOMA Ki-67  STAINING. LI- 42 % (10X). 
  
 
 
FIGURE 24 A: MUCINOUS BORDERLINE TUMOR  Ki-67 STAINING LI- 22%( 45X) 
 
 
FIGURE 24 B: MUCIONUS BORDERLINE TUMOR Ki-67 STAINING  LI- 28%.(10X) 
 
  
 
 
FIGURE 25: MUCINOUS CARCINOMA Ki-67 STAINING LI- 36%.(10X) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
              Ovaries are common sites of non-neoplastic and neoplastic lesions
83
. 
The anatomy of ovary is complex and its physiology peculiarly shows constant 
cyclical changes from puberty to menopause giving rise  to different cell types, 
each of which is capable of giving rise to complex  varieties of tumors
32
. 
 Two thirds of ovarian tumors occur in women of reproductive age 
group
92
. According to Glen mc clugge et al ovarian cancer is considered to be a 
silent Killer, as most of these tumors are identified at advanced stage of the 
disease(FIGO III or IV)and  hence overall prognosis is poor
32
.                          
  Although ovarian tumors are considered as one disease clinically; it is being 
increasingly realised that the different morphological subtypes has different 
pathogenesis and are associated with distinct molecular alterationsand  have 
different prognosis
24
. 
In this study, about 11,726 surgical pathology specimens werereceived 
and analysed over a period of 2 1/2 years. Of these 626 weregynaecological 
tumors, among which ovarian neoplasms constitutes 150cases, accounting for 
about 23.9% of all  gynaecological tumors.                
 
 
I.INCIDENCE: 
       In our study we observed that the ovarian malignancy accounted for 
2.6%of all female malignancies and is given in the following table.19 
[CHART11] 
TABLE:19 :  INCIDENCE OF MALIGNANT OVARIAN TUMORS IN 
RELATION TO TOTAL MALIGNANCIES IN FEMALES. 
 
SL.NO 
 
 PERIOD 
TOTAL NO OF 
MALIGNANCIES 
IN FEMLAES 
TOTAL NO OF 
MALIGNANT 
OVARIAN 
NEOPLASMS 
 
% 
1. Jan10-
May10 
276 7 0.6% 
2. Jun10-Dec10 242 6 0.5% 
3. Jan11-
May11 
189 7 0.6% 
4. Jun11-Dec11 277 5 0.4% 
5. Jan12-
May12 
106 4 0.3% 
 Total 1090 29 2.6% 
 
 
 
 
 
  
 
CHART 11: INCIDENCE OF MALIGNANT OVARIAN TUMORS IN RELATION TO TOTAL FEMALE 
MALIGNANCY 
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CHART 12: INCIDENCE OF INDIVIDUAL MALIGNANT OVARIAN TUMORS 
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MALIGNANT TUMORS 
Papillary serous carcinoma
Mucinous carcinoma
Granulosa cell tumor
Dysgerminoma
Mixed germ cell tumor
Metastatic tumor
 II :  INCIDENCE OF  HISTOLOGICAL TYPES OF MALIGNANT  
TUMORS IN RELATION  TO TOTAL OVARIAN MALIGNANCIES.  
TABLE 20:   
HISTOLOGICAL 
TYPE 
NO.OF CASES % of Total 
Malignant 
Ovarian 
Tumors(29) 
%  Incidence of 
Total Ovarian 
tumors(150) 
Papillary Serous 
cystadenocarcinoma 
10 34.4 6.6 
Mucinous 
cystadenocarcinoma 
4 13.7 2.6 
Granulosa Cell 
Tumor 
9 31.03 6 
Dysgerminoma 1 3.44 0.6 
Mixed germ cell 
tumor 
1 3.44 0.6 
Metastatic 
adeno/krukenberg 
4 13.7 2.6 
 
From the above table.20 it is evident that , of  the total 29 malignant  
ovarian tumors , most common was  papillary serous cystadenocarcinoma 
accounting for about 34.5%(10/29) , followed by granulosa cell tumor  
accounting for  31 %(9/29) and mucinous adenocarcinoma & metastatic tumors  
accounting for 13%(4/29) each. The least common type in this study was 
dysgerminoma(1/29 cases). [CHART 12]. 
III.  INCIDENCE OF OVARIAN CARCINOMA IN RELATION TO 
OTHER STUDIES 
TABLE 21: 
SL.NO PLACE OF STUDY INCIDENCE 
1. Grant medical college and sir J.J group of 
hospitals ,Mumbai 
7.8% 
2. Dr.BR Ambedkar institute hospital, New 
delhi 
7.5% 
3. Adyar cancer institute,Chennai 5.1% 
4. Chittaranjan National cancer institute 5.8% 
5. Dindigul ambilikai cancer registry 3.3% 
6. Barshi rural registry,Maharashtra 3.8% 
7. Present study 2.6% 
 
It is evident from the above table. 21 .that Mumbai holds the top ranking 
with the incidence rate of 7.8% and the least is Dindigul ambilikai cancer 
registry with the incidence rate of 3.3%. This study conducted in a semi urban 
area; showed an incidence rate of ovarian malignancy (2.6%) is in midway 
between rural and urban area. [CHART13]. 
 
 
  
 IV. INCIDENCE OF OVARIAN MALIGNANCIES IN RELATION TO 
FEMALE GENITAL TRACT MALIGNANCIES, TABLE 22: 
 
SL.NO 
 
SITE 
NO.OF FEMALE GENITAL 
TRACT MALIGNANCIES 
 
% 
1. Cervix 575 91% 
2. Ovary 29 4.7% 
3. Endometrium 16 2.5% 
4. Vulva 6 1% 
5. Vagina - - 
6. Fallopian tube - - 
 Total 626  
 
From the above table.22, it was  observed that ovarian malignancies are 
the second common(4.7%) malignancy among all female genital tract 
malignancies.  It was also observed that uterine cervix (91%) was found to be 
the first most common site to be involved , and the  least common site is 
vulva.[CHART 14] 
The age specific incidence of ovarian neoplasms ranges from 20-70 years . 
According to Min jae kim et al  the incidence of benign neoplasms peaks  in 2
nd
 
-3
rd
 decade of life
93,94
. In this study,  benign neoplasms were commonly 
observed in 20-29 yrs of age which is well correlated with our study. According 
to Debra et al, the  incidence of borderline ovarian tumors peaks in 4
th
 decade. 
In our study borderline ovarian tumors are common in 40-50yrs age group. This  
finding is well correlated with previous studies and literature {6,21}.  
 
 
 
CHART 14: INCIDENCE OF OVARIAN MALIGNANCIES IN RELATION TO FEMALE GENITAL 
TRACT MALIGNANCIES 
 
 
 
 
In this  study malignant ovarian tumors are common in 5
th
-6
th
 decade. 
This in accordance with study conducted byshruti shah et al
88
, who showed that 
42.5% patients with malignant tumors  were in the age group of  51-60yrs.  
Similar findings were noted in other studies [24,32].        
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Ovarian  cancers  are considered as a silent killer, as they present at an 
advanced stage of the disease due to the non specific symptoms. Most common 
presenting symptom in our study was abdominal mass(80%),followed by pain 
abdomen(7%). This is similar to a study conducted byHiermath et al in 
Pondicherry which showed that abdominal mass ispresenting symptom 
accounting for 84% cases followed by abdominal pain (12%).  
In this study; 14 cases ,constituting for about 9% of all ovarian tumors 
showed bilateral involvement at the time of presentation. Of which 5 cases 
(35%) were benign, 1 case(7%) were borderline, 8 cases(57%) were malignant.  
Among malignant tumors, bilaterality is commonly observed in malignant 
serous group (4/8, 50%), followed by metastatic tumor(3/8,37%). This is 
inaccordance with study conducted by R Jha et al
78  
. 
In this study, 72.6% ovarian tumors were benign and 19.3% were 
malignant. This is similar to the data from a study  by Pilli et al in India which 
showed that 75.2% were benign, and a similar study conducted by samina et 
alin Pakistan which showed similar results with 78% benign tumors and 21 % 
were malignant. Comparison of incidence of benign and malignant ovarian 
tumors in our study in relation to various other studies are given in the 
following table 23.[ CHART15] 
 
  
 
CHART 15: INCIDENCE OF OVARIAN TUMORS IN RELATION TO OTHER STUDIES 
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CHART 16: COMPARING THE INCIDENCE OF HISTOLOGICAL TYPES OF OVARIAN TUMORS IN 
RELATION TO OTHER STUDIES
 
 
TABLE 23 :  INCIDENCE OF OVARIAN TUMORS IN OUR STUDY 
IN RELATION TO OTHER STUDIES: 
Author  PLACE OF 
STUDY 
BENIGN MALIGNANT 
R Jha et al Nepal  83.9% 16% 
Pilli et al India 75.2% 24.8% 
Ahmed et al Pakistan  59.2 % 40.8% 
GG Swamy et al Nepal  71.6% 30% 
Present study Thanjavur  72.6% 19.3% 
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 Among  all ovarian tumors ,surface epithelial tumors was the most 
common, accounting  for about 72.6%  followed by germ cell tumors(16%) and  
sex cord stromal tumors (8.6%).The data obtained in this study well correlates 
with the study conducted by sumaira et al in Pakistan which showed that surface 
epithelial tumors predominates with 76.5% ,followed by germ cell 
tumors(18%). Following table 24 compares the incidence of histological types 
of  ovarian tumors in this study in relation to other study .[CHART16] 
 
 
 
 
TABLE 24 : COMPARISON OF INCIDENCE OF HISTOLOGICAL 
TYPES OF OVARIAN TUMORS  WITH OTHER STUDIES. 
Author  Place of 
study 
Surface 
epithelial 
tumor 
Germ cell 
tumor 
Sex cord 
stromal 
tumor 
Metastases  
Samina et al Pakistan  68.5% 23% 8.6% 2.6% 
GG Swamy 
et al 
Nepal  61.6% 21.7% 11.7% 5% 
Pilli GS et al India  71% 18% 9.6% 1.2% 
Present study Thanjavur  72.6% 16% 8.6% 2.6% 
 
 
In this study among the surface epithelial tumors , most common 
wereserous tumors accounting  for 56% , followed by mucinous tumors (41%). 
Among serous tumors, 78.6% were benign, 4.9% were borderline,16.3% were 
malignant. This is in accordance with study conducted by R Jha et al inNepal 
which showed that benign serous tumors were the commonest (78.9%) followed 
by malignant serous tumors (22%). Following table.25  and 26 compares the  
incidence of histological subtypes of surface epithelial tumors in relation to 
other studies. [CHART17] 
 
 
 
CHART 17: COMPARING THE INCIDENCE OF HISTOLOGICAL SUBTYPES OF SURFACE 
EPITHELIAL TUMORS IN REALTION TO OTHER STUDIES 
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CHART 18: COMPARING THE INCIDENCE OF SEROUS TUMORS IN RELATION TO 
OTHERSTUDIES 
 
 
 
TABLE 25:  COMPARISON  OF INCIDENCE OF HISTOLOGICAL 
SUBTYPES OF  SURFACE  EPITHELIAL TUMORS  IN RELATION 
TO OTHER STUDIES: 
AUTHOR  PLACE OF 
STUDY  
SEROUS  MUCINOUS  TRANSITIONAL  
GGSwamy et al India  77% 19% - 
Samina et al Pakistan  66% 18.7% 2.2% 
Present study Thanjavur  56% 41.2% 2.75% 
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TABLE 26 : COMPARISON OF INCIDENCE OF  SEROUS TUMORS IN 
RELATION TO OTHER  STUDIES. 
AUTHOR  PLACE OF 
STUDY 
BENIGN  BORDERLINE MALIGNANT 
Hiremath et al Pondicherry  46% 8% 13.5% 
Samina et al Pakistan  38% 2% 4.5% 
Fattaneh et al India  60% 10% 30% 
Present study Thanjavur  78% 5% 16.3% 
 
According to the Jefferey et al
43
 and Geza et al
21
, Serous borderline 
ovarian tumors are the most common histological subtype of borderline tumors 
accounting for 65%  of all borderline ovarian tumors
21
. In contrast, mucinous 
borderline tumors were common in our study accounting for about 75%  cases 
and serous borderline for 25%. 
According to Neeraj lalwani et al
65
, approximately 1/3
rd
 of serous 
borderline tumors are bilateral . In this study also 1/3
rd
( 1case,33%) were 
bilateral. About 20-30% of serous borderline ovarian tumors were associated  
with peritoneal implants
21
. In contrast, in this study none of the serous 
borderline tumors had associated peritoneal implants at the time of presentation. 
 
According to Glen mc cugage et al 
24
& other studies, it is well established 
that there are two distinct types of serous carcinoma, namely low grade and high 
grade, low grade being much less common and arising from a serous borderline 
tumor .In this  study there are about 10 cases of serous carcinoma, of which 6 
cases(60%)  were high grade and 4 cases(40%) were of low grade was 
observed. 
According to Anais malpaica et al
3
,Ovarian serous carcinomas are 
classified into low grade and high grade according to recent 2-tier grading 
system, which is based primarily on the assessment of nuclear atypia with 
mitotic rate as a secondary feature. Recent 2 tier grading system is based on the 
evidence that low and high  grade tumors arise from different genetic 
pathways
3
. 
According to Jefferay SD et al
44
 surface epithelial tumors are classified 
into TypeI and Type II tumors which corresponds to two main pathways of 
tumorigenesis. 
According to Russel vang et al
80
 Type I tumors are indolent neoplasms 
that develop in a slow stepwise process from borderline tumors. They typically 
present as stage I tumors and remain as low grade tumors but can progress to 
high grade tumors. They include low grade serous carcinoma, mucinous 
carcinoma, endometroid carcinoma, malignant  Brenner tumor and clear cell 
carcinomas
80
.   
 In contrast type II tumors are high grade, arise as denovo, rapidly 
evolving , aggressive neoplasms and they typically present as advanced stage 
disease
76,80
. They include high grade serous carcinoma, Malignant mixed 
mullerian tumor and undifferentiated carcinoma. 
In addition to clinical and pathological differences between low grade and 
high grade serous carcinoma, they are also characterised by distinctive 
molecular genetic changes
80
. Low grade serous carcinomas typicallyshows 
KRAS & BRAF mutations and lack p53 mutations
73
. High grade seroustumors  
are characterised by p53 mutations and lack KRAS & BRAF mutations
73
.  
In this study mucinous tumors are the second most common type of 
surface epithelial tumors, of which 70% are benign,21% are borderline and 9% 
are malignant. This is in contrast to journals and literature where borderline 
mucinous tumors accounts for only 10% and malignant mucinous tumors also 
accounts for 10 % of tumors
76
. Following table .27compares the incidence of 
mucinous tumors in relation to other studies. [chart19]. 
 
 
 
 
 
 
CHART 19: COMPARING THE INCIDENCE OF MUCINOUS TUMORS IN RELATION TO OTHER 
STUDIES 
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 TABLE 27 : INCIDENCE OF MUCINOUS TUMORS IN RELATION TO 
OTHER STUDIES: 
Author  Place of study Benign  Borderline  Malignant  
Hiremath et al Pondicherry  76% 6.5% 17.5% 
R Jha et al Nepal 75% 10% 15% 
Fattaneh et al India  80% 10% 10% 
Present study Thanjavur  70% 21% 9% 
 
There are about 3 benign Brenner tumors in this study accounting for  3% of 
all  benign surface epithelial tumors. This is in accordance with the journals and 
literature
16
 
Brenner tumors are often associated with other tumors such as ucinous 
cystadenoma and mature cystic teratoma
44,33
. Inthis study one suchassociation of 
Brenner tumor with mucinous cystadenoma was found.          According to 
Tsunehisa kaku et al presence of endometriosis is associated  with high 
incidence of ovarian carcinomas , particularly endometrioid  carcinoma,  clear 
cell carcinoma, mucinous and serous carcinomas
102,41
. In contrast none of the 
ovarian tumors  in this study was found to be associated with endometriosis. 
In this study there are about 24 cases of germ cell tumors, accounting for 
16% of all ovarian tumors. Among germ cell tumor group, mature 
cysticteratoma was the commonest accounting for 91.6%,followed by 
dysgerminoma,4.1% and mixed germ cell tumor, 4.1%.This is in 
accordancewith the study conducted by Fred ureland et al 
15
and Kwok et al
46
. 
According to P.Singh et al 
90
, age at presentation for malignant  
transformation in dermoid cyst is older than those with benign disease and is 
more common in postmenopausal age group. In contrast there were three cases 
in postmenopausal age group in our study but none of them showed malignant 
transformation. 
According to P.singh et al 
90
 and Gary et al
19
 , Dermoid cysts were the 
commonest ovarian tumor associated with pregnancy . Similarly in our study , 
common tumor associated with pregnancy was dermoid cyst, followed by 
benign mucinous cystadenoma. One case of dysgerminoma and 1 case of mixed 
germ cell tumor with combination of dysgerminoma and yolk sac tumor 
component was observed in ourstudy. 
 
In this study, a total of 13 cases, of sex cord stromal tumor accountingfor 
8.6% of all ovarian tumors was observed. Of  which granulosa cell tumor was 
the most common type with 9 cases(69%),followed by fibroma with 3 
cases(23%),followed by fibrothecoma  1 case,(8%). This finding in our study 
well correlates with thestudy conducted by R Jha et al
78 
According to Lawrence et al
49
 more than 95% of adult granulosa cell 
tumors are unilateral. Similarly in this study 9/9 cases were unilateral at the time 
of presentation .According to Fattaneh et al
16
 granulosa cell tumors can be 
associated with endometrial neoplasia. However in this study, none of the 9 
cases had any association with endometrial neoplasia. 
 According to Sung-Jong et al 
98
, metastatic tumors to the ovaryaccounts 
for about 5-10% of all ovarian neoplasms. General features of ovarian 
metastases include bilaterality, surface involvement, extensive extraovarian 
spread , vascular invasion, desmoplastic reaction & unusual clinical history
45,54
. 
          According to masaki mandai et al
59 
,  Krukenberg tumor is the most 
common form of ovarian  metastatic carcinoma, often found in the 4
th
decade. It 
is applied to a clinicopathological   entity characterised by presence of mucin –
filled , signet ring tumor cells within cellular stroma
59
. In this study, 3 cases 
ofkrukenberg tumor and one case of  metastatic adenocarcinomatous deposits in 
one ovary of intestinal origin was  observed. 
In this study p53 immunohistochemical staining of  serous carcinomas 
was done after classifying them as low grade and high grade based on recent 2 
tier grading system
3
. Of the 4 low grade serous tumors  ,3 (75%) of them 
stained negatively for p53 . Of the six high grade serous tumors, 5 (90%) of 
them showed positivity for p53. Of the 4 cases of mucinous carcinoma, al 
showed negativity for p53. This finding in  our study is well correlated with the 
studies conducted by Russell Vang et al
80
 and Gad Singer etal
17
. 
          Understanding the pathogenesis of Type I and Type II tumors 
providesclues for new approaches to early detection and treatment
48
.  
         According to Russel pury et al and Scotters et al , although discrepancies 
exist , epithelial ovarian malignancies showing p53 aberrations are  significantly 
less sensitive to platinum based chemotheraphy and more aggressive than those 
with functional p53  and hence overexpression of p53 isa poor prognostic 
factor
52,79
. 
 
Tumors of borderline category tends to occur in younger women, often 
less than 40 yrs of age. Role of conservative surgery may be considered in 
patients who desire to preserve fertility. However these patients has to 
becarefully followed up  with routine pelvic examinations, serial CA-125 serum 
levels,  ultrasound examination. 
According to Steven G. Silverberg et al
95
 borderline tumors  constitute a 
unique group characterised by an unusual degree of epithelial cell proliferation 
and atypia when compared with benign neoplasms. But these borderline tumors 
lacks stromal invasion which is the characteristic feature ofinvasive tumors
95
. 
The clinical course of these borderline tumors is in between benign and 
malignant; they are known to metastasize within the peritoneal cavity but rarely 
results in death
65
.   
According to Shappel et al 
87
, in particular Mucinous borderline tumors, 
due to the gross and microscopic multiloculation , the identification of 
stromalinvasion is inherently more difficult . Although several studies  
including Terilowski et al 
100 
suggest that the presence of markedly atypical 
nuclei andstratification to a degree greater than three should prompt the 
diagnosis ofwell differentiated mucinous carcinoma, even in the absence of 
frank stromalinvasion
100
.                        
                According to Veronique et al
104
 morphological changes in the nuclei 
ofneoplastic cells and their proliferative activity are a significant element 
ofhistopathlogical examination. In many cases, traditional techniques 
cannotdefine precisely grading of malignancy, the best evidence of which is  
tumorsof borderline category
81
. 
               According to Swang maxy
99
 et al , proliferative activity of malignant 
tumors are usually higher than benign and borderline tumors.Determination of 
proliferative activity of tumors by  ki-67  labeliing indexthrough the analysis of  
MIB-1 monoclonalantibody reactivity will help indifferentiating borderline and 
malignant tumors. 
              According to GuroAune et al and Henzen et al, patients with ovarian 
tumors demonstrate potential usefulness of ki-67 antigen expression and  its role 
in predicting the outcome in ovarian cancer. According to  Henzen et al 
,Terilowski et al and Nesrin gursan et al ,  malignant  epithelial neoplasm had 
astatiscally  significant  higher mean  ki-67 expression than borderline 
tumors
34,66,100
. Following table 28 , compares the ki-67 labelling index in 
epithelial ovarian tumors in this study and  various other studies. 
 
 
 
TABLE 28 : COMPARISON OF KI-67 LI IN EPITHELIAL OVARIAN 
TUMORS WITH  OTHER  STUDIES: 
AUTHOR  PLACE OF 
STUDY 
BENIGN  BORDERLINE  MALIGNANT 
Nesrin gursan et 
al 
Turkey  14.9% 22.8% 42.8% 
Shunji mita et al Japan 12.3% 21.3% 48.9% 
Monisha choudry 
et al 
India  6.9% 18% 49% 
Terilowsky et al Poland  - 23% 36% 
Buchynska et al Ukraine 8.9% 21% 63% 
Present study Thanjavur  - 25% 42% 
 
In this study  , mean ki-67 expression of malignant epithelial tumors  was 
42% when compared to borderline tumors  with a mean ki-67 LI of 25% and 
this difference was found to be statistically significant. Statistical analysis was 
carried out using Students t –test.Shunji mita et al89, had demonstrated   
 
CHART 20: COMPARING Ki-67 LABELLING INDEX IN EPITHELIAL OVARIAN TUMORS 
IN RELATION TO OTHER STUDIES 
 
 
 
15 
12 
9 
7 6.9 
23 
18 
19 
23 
20 
25 
43 
49 
63 
36 
49 
42 
0
10
20
30
40
50
60
70
Nesrin
gursan et al
Shunji mita
et al
Buchynska
et al
Terilowski et
al
Monisha
choudry etal
Present
study
P
ER
C
EN
TA
G
E 
Benign
Borderline
Malignant
  
 
 
Significant  relationship between  ki-67  antigen  expression  and  long term 
survival  and its  role in  predicting patients  outcome in surface  epithelial 
tumors
89
. 
 
Although the staining pattern for ki-67  in predicting malignant versus 
borderline  tumors  is statistically significant, they are applied only in difficult 
cases
55
. According to Lobna ayadi et al and Mary T Sylvia et al , more 
importantly a panel of markers like p53, bcl-2 and ki-67 , all of which 
reflectsthe proliferative activity of the tumor should be used and it may further 
definethe biologic potential of a specific tumor
{66,55,57}.
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 CONCLUSION 
  
              In our study a total of 150 cases were evaluated   with clinical , 
histopathological  & immunohistochemistry and the following conclusions   
were  made  and presented. 
 
1. The incidence of ovarian neoplasms among all  female  neoplasms is  
7.8% 
 
2. The incidence of ovarian malignancies among all female malignancies is 
2.6% 
 
3. Ovarian malignancy ranks 2nd (4.7%) among  the female genital tract  
Malignancies. 
 
4. The ratio of benign and malignant ovarian neoplasm is 3:1 
 
5. The incidence of ovarian neoplasm is  highest during the  2nd  decade  
followed  by 4
th
  decade. 
6.  90%  of ovarian neoplasms are unilateral and 10% are bilateral at the  
time of  presentation 
 
7. Benign neoplasms are predominantly cystic, whereas malignant  
neoplasms  are predominantly solid and cystic or purely solid. 
 
8. Surface epithelial tumors are the most common neoplasm of which  
Serous cysadenoma is the commonest. 
 
9. Detecting  p53 mutations by immunohistochemistry in surface epithelial 
neoplasms  helps to understand the pathogenesis of  Type I and Type II 
ovarian neoplasms. 
 
10.  Increased expression of Ki-67 LI  was found in malignant  surface    
epithelial  neoplasms  when compared to borderline  epithelial   
neoplasms and it is statistically significant. 
 
This study is an institution based  one and has small sample size of 150 
cases. So the results obtained may or may not reflect the actual histological 
pattern and age distribution of ovarian cancer in Indian women. The 
epidemiological pattern of cancers in developing countries differs in many 
aspects from developed nations. The age specific incidence of ovarian cancer 
and its subtypes presented in this study will serve as a useful point of reference 
for future studies and would help to specify  their trend in future and encompass 
the community health programs to solve health problems.  
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APPENDIX I 
HAEMATOXYLIN AND EOSIN STAIN 
Preparation of solution : 
HARRIS HAEMATOXYLIN 
Distilled water-1000ml 
Ammonium alum-100g 
Absolute ethyl alcohol-50ml 
Mercuric oxide-2.5g 
100g of ammonium alum dissolved in 1000ml of distilled water by heating and 
shaking at 60.c .Add solution of 5g of haematoxylin in 50ml of ethylalcohol and  
bring rapidly to boil.when it begins to boil,remove from flame and add 2.5 g of  
mercuric oxide. Mix by swirling gently. 
EOSIN STAIN 
Eosin  Y- 1 g. 
Distilled water-20ml. 
95% ethanol-80ml 
Glacial acetic acid-0.2ml 
Dissolve 1 gm of eosin Y in 20ml of water ,add 80 ml of 95% ethyl alcohol and  
0.2 ml of glacial acetic acid. 
 
 
 
 
Procedure : 
1. Bring the sections to water 
2. Dip in Harris haematoxylin for 15 minutes. 
3. Rinse in tap water. 
4. Differentiate in 1% acid alcohol-3-4 quick dips. 
5. Wash in tap water briefly. 
6.  Dip in ammonia water or saturated lithium carbonate  until the sections 
are blue. 
7.  Wash in running tap water for 10-20 minutes. 
8.  Stain with eosin for 15 seconds to 2 minutes depending on the age of 
the eosin and the depth of counter stain. 
9. Rinse in tap water. 
    10.  Dip in 95% alcohol 
    11.  3 changes in absolute alcohol. 
    12.  Xylene – 2 changes. 
    13.  Mount in DPX mountant. 
 
 
APPENDIX II 
IMMUNOHISTOCHEMISTRY 
PREPARATION OF SOLUTIONS: 
Tris buffer saline (TBS): 0.005M 
Distillled water-10 litres 
Sodium chloride- 80gms 
Tris (hydroxymethylamine)-6.05g 
1 M Hcl-44 ml. 
Final  pH is adjusted to 7.6 with either 1 M Hcl or 0.2 M Tris solution. 
CITRATE BUFFER SOLUTION: 
Trisodium citrate-2.94 gm 
1 N Hcl-5ml 
Distilled water-1000 ml 
Final ph is adjusted to 6.0 with 1 N H cl. 
Preparation of gelatine coated slides: 
Chrome alum-0.05gm 
Gelatine-0.3 gm 
Distilled water-100 ml. 
Chrome alum is added to distilled water and then hheated to 60.c.gelatin is  
added slowly to the heated  distilled water. Glass slides are then dipped in this  
solution and dried overnight. 
Antigen retrieval: 
The slides are placed in citrate buffer in the coplin jar and capped. The jar is  
then heated in a 750 W domestic microwave oven for 15 minutes. 
Procedure : 
1. Dewax the section  in xylene(1/2 hr, 2 changes) and bring sections to  
distilled water. 
2. Antigen retrievel using TBS by microwave oven heating 
3. Cool to room temperature in running tap water for 20 mintues. 
4. Bring the section toTBS for 5 minutes. 
5. Drain and wipe off excess TBS around sections 
6. Incubate in endogenous peroxidise blocking agent for 15-20 minutes. 
7. Gently wash the slide in TBS for 5 minutes. 
8. Wipe off excess fluid and incubate in power block for 15-20 minutes 
9. Blot and dry excess  power block. 
10. Incubate in primary antibody for 60 minutes. 
11. Repeat steps 4 and 5 . 
12. Incubate in superenhancer for 30 minutes. 
13. Repeat steps 4 and 5. 
14. Incubate in secondary antibody for 30 minutes. 
15. Repeat steps  4 and 5  
16. Incubate in DAB(DiaminoBenzidine) substrate buffer for 2-10 minutes 
17. Wash in distilled water counter stain with haematoxylin,clear in xylene 
and mount with DPX. 
                                                                            APPENDIX III 
Tumor, Node, Metastasis(TNM) Staging Scheme for ovarian carcinomas: 
PRIMARY TUMOR (T) 
TNM Category   International Federation of Gynaecology and Obstetrics-FIGO                     
TX                          Primary tumor cannot be assessed  
T0                          No evidence of primary tumor 
T1  I                        Tumor limited to ovaries(one or both) 
T1a   1A                 Tumor limited to one ovary; capsule intact, no tumor on  
surface or no malignant cells in ascites/ peritoneal washings. 
T1b  IB                   Tumor limited to both ovaries, capsule intact, no tumor on  
surface or no malignant cells in ascites/ peritoneal washings.   
T1c   IC                   Tumor limited to one or both ovaries with any of the                          
following:  capsule ruptured, tumor on ovarian surface,     
malignant cells in ascites or peritoneal washings. 
T2   II                      Tumor involves one or both ovaries with pelvic extension  
and/or implants 
T2a  IIA                   Extension and/or implants on uterus and /or tubes. No  
malignant cells in ascites or peritoneal washings 
T2b   IIB                   Extension to and/or peritoneal implants to other pelvic  
tissues. No malignat cells in ascites or peritoneal washings. 
T2c    II C                  Pelvic extension and/or implants with malignant cells in  
peritoneal washings or ascites. 
T3  and/or N1 III     Tumor involves one or both ovaries with microscopically  
confirmed peritoneal metastasis outside the pelvis. 
T3a   IIIA                  Microscopic peritoneal metastasis beyond the pelvis (no  
macroscopic tumor). 
T3b   III B                Macroscopic peritoneal metastasis beyond the pelvis < 2 cm  
in greatest dimension. 
T3c   III C                 Macroscopic peritoneal metastasis beyond the pelvis > 2 cm  
in greatest dimension. 
M1  IV                     Distant metastasis (excludes peritoneal metastasis) 
REGIONAL LYMPHNODE (N): 
NX                           Regional lymph nodes cannot be assessed 
N0                            No regional lymphnode metastasis. 
N1                            Regional lymphnode metastasis. 
DISTANT METASTASIS(M): 
MX                           Distant metastasis cannot be assessed 
M0                            No distant metastasis. 
M1                            Distant metastasis (excludes peritoneal metastasis). 
STAGE GROUPING: 
Stage IA:   T1a N0 M0 
Stage 1B: T1b N0 M0 
Stage 1C: T1c N0 M0 
Stage IIA: T2a N0 M0 
Stage IIB: T2b N0 M0 
Stage IIC: T2c N0M0 
Stage IIIA: T3a N0 M0 
Stage IIIB: T3b N0 M0 
Stage IIIC: T3c N0 M0 
                    Any T  N1 M0 
Stage IV : Any T  Any N  M1.    
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